MXPA99010843A - Skin care compositions - Google Patents
Skin care compositionsInfo
- Publication number
- MXPA99010843A MXPA99010843A MXPA/A/1999/010843A MX9910843A MXPA99010843A MX PA99010843 A MXPA99010843 A MX PA99010843A MX 9910843 A MX9910843 A MX 9910843A MX PA99010843 A MXPA99010843 A MX PA99010843A
- Authority
- MX
- Mexico
- Prior art keywords
- skin
- acid
- agents
- esters
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 239
- 210000003491 Skin Anatomy 0.000 title claims abstract description 156
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 18
- -1 iodopropargyl esters Chemical class 0.000 claims description 150
- 150000001875 compounds Chemical class 0.000 claims description 35
- 239000002537 cosmetic Substances 0.000 claims description 22
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 21
- 239000000516 sunscreening agent Substances 0.000 claims description 20
- 230000001105 regulatory Effects 0.000 claims description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 16
- 150000002170 ethers Chemical class 0.000 claims description 15
- 230000000475 sunscreen Effects 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 230000002335 preservative Effects 0.000 claims description 13
- 239000003755 preservative agent Substances 0.000 claims description 13
- 230000003750 conditioning Effects 0.000 claims description 12
- 150000001261 hydroxy acids Chemical class 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- VYGQUTWHTHXGQB-FFHKNEKCSA-N trans-Retinyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 6
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000000111 anti-oxidant Effects 0.000 claims description 5
- 230000001721 combination Effects 0.000 claims description 5
- 239000011769 retinyl palmitate Substances 0.000 claims description 5
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 5
- 229950004578 vitamin A palmitate Drugs 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 4
- 229940108325 retinyl palmitate Drugs 0.000 claims description 4
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 3
- WYVVKGNFXHOCQV-UHFFFAOYSA-N Iodopropynyl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 claims description 3
- 150000001241 acetals Chemical class 0.000 claims description 3
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 239000011604 retinal Substances 0.000 claims description 3
- 235000020945 retinal Nutrition 0.000 claims description 3
- 229960000342 retinol acetate Drugs 0.000 claims description 3
- 239000011770 retinyl acetate Substances 0.000 claims description 3
- 235000019173 retinyl acetate Nutrition 0.000 claims description 3
- 229940046305 5-bromo-5-nitro-1,3-dioxane Drugs 0.000 claims description 2
- XVBRCOKDZVQYAY-UHFFFAOYSA-N Bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 claims description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 claims description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N all-trans-retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 2
- BEQDKWKSUMQVMX-UHFFFAOYSA-N 2,4-dimethyl-4,5-dihydro-1,3-oxazole Chemical compound CC1COC(C)=N1 BEQDKWKSUMQVMX-UHFFFAOYSA-N 0.000 claims 1
- SOROIESOUPGGFO-UHFFFAOYSA-N Diazolidinyl urea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims 1
- 229940101011 SODIUM HYDROXYMETHYLGLYCINATE Drugs 0.000 claims 1
- 239000011717 all-trans-retinol Substances 0.000 claims 1
- 235000019169 all-trans-retinol Nutrition 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 claims 1
- 229960003471 retinol Drugs 0.000 abstract description 9
- 235000020944 retinol Nutrition 0.000 abstract description 7
- 239000011607 retinol Substances 0.000 abstract description 7
- 230000001815 facial Effects 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 description 71
- 239000003795 chemical substances by application Substances 0.000 description 66
- 239000012071 phase Substances 0.000 description 49
- 235000014113 dietary fatty acids Nutrition 0.000 description 46
- 239000000194 fatty acid Substances 0.000 description 46
- 239000000463 material Substances 0.000 description 41
- 239000004094 surface-active agent Substances 0.000 description 34
- 125000000217 alkyl group Chemical group 0.000 description 33
- 150000002148 esters Chemical class 0.000 description 33
- 150000003839 salts Chemical class 0.000 description 32
- 239000011780 sodium chloride Substances 0.000 description 31
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 30
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 30
- 230000032683 aging Effects 0.000 description 28
- 150000004665 fatty acids Chemical class 0.000 description 28
- 239000004615 ingredient Substances 0.000 description 27
- 239000000178 monomer Substances 0.000 description 27
- 229920001296 polysiloxane Polymers 0.000 description 27
- 239000000839 emulsion Substances 0.000 description 25
- 229960003512 nicotinic acid Drugs 0.000 description 25
- 230000033228 biological regulation Effects 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 239000003995 emulsifying agent Substances 0.000 description 24
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 22
- 229940008099 dimethicone Drugs 0.000 description 22
- 239000004205 dimethyl polysiloxane Substances 0.000 description 22
- 239000003981 vehicle Substances 0.000 description 22
- 229930003537 Vitamin B3 Natural products 0.000 description 21
- 235000019160 vitamin B3 Nutrition 0.000 description 21
- 239000011708 vitamin B3 Substances 0.000 description 21
- 239000002253 acid Substances 0.000 description 20
- 230000002209 hydrophobic Effects 0.000 description 20
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 19
- 239000005720 sucrose Substances 0.000 description 19
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 18
- 229920001577 copolymer Polymers 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 239000002562 thickening agent Substances 0.000 description 17
- 230000000699 topical Effects 0.000 description 17
- 150000001298 alcohols Chemical class 0.000 description 16
- 239000003974 emollient agent Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000004166 Lanolin Substances 0.000 description 14
- 229940039717 Lanolin Drugs 0.000 description 14
- 235000019388 lanolin Nutrition 0.000 description 14
- 206010040844 Skin exfoliation Diseases 0.000 description 13
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- 239000003085 diluting agent Substances 0.000 description 12
- 150000002430 hydrocarbons Chemical class 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 230000037303 wrinkles Effects 0.000 description 12
- 125000002091 cationic group Chemical group 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- 239000002736 nonionic surfactant Substances 0.000 description 11
- 229920000570 polyether Polymers 0.000 description 11
- 239000004721 Polyphenylene oxide Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 125000004432 carbon atoms Chemical group C* 0.000 description 10
- 150000002191 fatty alcohols Chemical class 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 9
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 239000002260 anti-inflammatory agent Substances 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000003349 gelling agent Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 238000009835 boiling Methods 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 8
- 230000035618 desquamation Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 229920000058 polyacrylate Polymers 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 239000002888 zwitterionic surfactant Substances 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 7
- 229920001451 Polypropylene glycol Polymers 0.000 description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 7
- 150000001735 carboxylic acids Chemical class 0.000 description 7
- 229960000541 cetyl alcohol Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229920001519 homopolymer Polymers 0.000 description 7
- 229920001888 polyacrylic acid Polymers 0.000 description 7
- 239000002516 radical scavenger Substances 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 229940053487 Niacinamide Drugs 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 229960001295 Tocopherol Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 229940086555 cyclomethicone Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 238000011068 load Methods 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- 229930003799 tocopherols Natural products 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- WXZMFSXDPGVJKK-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 5
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 5
- MVQVNTPHUGQQHK-UHFFFAOYSA-N Nicotinyl alcohol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 5
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 5
- FMJSMJQBSVNSBF-UHFFFAOYSA-N Octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 150000001253 acrylic acids Chemical class 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000002280 amphoteric surfactant Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000007854 depigmenting agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000004676 glycans Polymers 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 229920005862 polyol Polymers 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Polymers 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 229940113118 Carrageenan Drugs 0.000 description 4
- 229940085262 Cetyl dimethicone Drugs 0.000 description 4
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- OYHQOLUKZRVURQ-UHFFFAOYSA-N Linoleic acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 4
- 229940098695 Palmitic Acid Drugs 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 229940075554 Sorbate Drugs 0.000 description 4
- 229960001727 Tretinoin Drugs 0.000 description 4
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 4
- 125000005250 alkyl acrylate group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 229940121363 anti-inflammatory agents Drugs 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 229940116224 behenate Drugs 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000003093 cationic surfactant Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 150000001993 dienes Chemical class 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- FIKFOOMAUXPBJM-UHFFFAOYSA-N hepta-2,5-dienediamide Chemical class NC(=O)C=CCC=CC(N)=O FIKFOOMAUXPBJM-UHFFFAOYSA-N 0.000 description 4
- CMBYOWLFQAFZCP-UHFFFAOYSA-N hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 4
- 229940100463 hexyl laurate Drugs 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 229960000601 octocrylene Drugs 0.000 description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000000069 prophylaxis Effects 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000020238 sunflower seed Nutrition 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- QYKIQEUNHZKYBP-UHFFFAOYSA-N vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-(1R,3R,4S)-menthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 3
- UVCJGUGAGLDPAA-UHFFFAOYSA-N 2-phenyl-3H-benzimidazole-5-sulfonic acid Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 3
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 description 3
- 240000005513 Aloe vera Species 0.000 description 3
- VLPFTAMPNXLGLX-UHFFFAOYSA-N Axona Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229940107161 Cholesterol Drugs 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 3
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 3
- 229920004511 Dow Corning® 200 Fluid Polymers 0.000 description 3
- XILVEPYQJIOVNB-UHFFFAOYSA-N Etofenamate Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 3
- AAXVEMMRQDVLJB-BULBTXNYSA-N Fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 3
- 229960002011 Fludrocortisone Drugs 0.000 description 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N Flufenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 3
- 210000004209 Hair Anatomy 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 229940099367 LANOLIN ALCOHOLS Drugs 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- FQPSGWSUVKBHSU-UHFFFAOYSA-N Methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 3
- XJRBAMWJDBPFIM-UHFFFAOYSA-N Methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- 229940049964 Oleate Drugs 0.000 description 3
- 229940100460 PEG-100 Stearate Drugs 0.000 description 3
- 229940115476 PPG-1 TRIDECETH-6 Drugs 0.000 description 3
- 235000019482 Palm oil Nutrition 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 125000005466 alkylenyl group Chemical group 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000003078 antioxidant Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960005193 avobenzone Drugs 0.000 description 3
- 244000052616 bacterial pathogens Species 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 239000008406 cosmetic ingredient Substances 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229940031578 diisopropyl adipate Drugs 0.000 description 3
- 229960000735 docosanol Drugs 0.000 description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229960001493 etofenamate Drugs 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 231100001045 histological change Toxicity 0.000 description 3
- 230000036732 histological change Effects 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940049918 linoleate Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 3
- 239000002540 palm oil Substances 0.000 description 3
- 239000011236 particulate material Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- CZJXBZPJABCCRQ-BULBTXNYSA-N (8S,9R,10S,11S,13S,14S,17R)-9,11-dichloro-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C=C[C@]2(C)[C@@]3(Cl)[C@@H](Cl)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 CZJXBZPJABCCRQ-BULBTXNYSA-N 0.000 description 2
- WBHHMMIMDMUBKC-QJWNTBNXSA-M (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 2
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-Butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 description 2
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 2
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-Methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 2
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 2
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 2
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 2
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical group C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 2
- YDIYEOMDOWUDTJ-UHFFFAOYSA-N 4-(DIMETHYLAMINO)BENZOIC ACID Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-N 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N ARBUTIN Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 241000487074 Alosa alosa Species 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N Arachidic acid Natural products CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- 229940092703 Beclomethasone Dipropionate Drugs 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- ATEFPOUAMCWAQS-UHFFFAOYSA-N Daphnetin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 description 2
- 229950009888 Dichlorisone Drugs 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 210000002615 Epidermis Anatomy 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N Erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- ILEDWLMCKZNDJK-UHFFFAOYSA-N Esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N Felbinac Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 2
- 229960003721 Fluclorolone acetonide Drugs 0.000 description 2
- NJNWEGFJCGYWQT-VSXGLTOVSA-N Fluclorolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1Cl NJNWEGFJCGYWQT-VSXGLTOVSA-N 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Fludroxycortide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- 229960004369 Flufenamic Acid Drugs 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N Gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940074047 Glyceryl Cocoate Drugs 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- 240000005389 Glycyrrhiza glabra Species 0.000 description 2
- LPLVUJXQOOQHMX-MYOOOWEVSA-N Glycyrrhizic acid Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1 LPLVUJXQOOQHMX-MYOOOWEVSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N Kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229940078752 MAGNESIUM ASCORBYL PHOSPHATE Drugs 0.000 description 2
- 229940078812 MYRISTYL MYRISTATE Drugs 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N Methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HOVAGTYPODGVJG-WLDMJGECSA-N Methylglucoside Chemical class COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-WLDMJGECSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- IYCHDNQCHLMLJZ-UHFFFAOYSA-N N-hydroxypyridine-3-carboxamide Chemical compound ONC(=O)C1=CC=CN=C1 IYCHDNQCHLMLJZ-UHFFFAOYSA-N 0.000 description 2
- ZBSGKPYXQINNGF-UHFFFAOYSA-N N-nicotinoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CN=C1 ZBSGKPYXQINNGF-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- 229940066842 Petrolatum Drugs 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019774 Rice Bran oil Nutrition 0.000 description 2
- 229940066675 Ricinoleate Drugs 0.000 description 2
- 229940098760 STEARETH-2 Drugs 0.000 description 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- 229940045997 Vitamin A Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 Xylitol Drugs 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- RIQIJXOWVAHQES-OWUNKUSISA-N [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (2Z,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C RIQIJXOWVAHQES-OWUNKUSISA-N 0.000 description 2
- SCMSRHIBVBIECI-UHFFFAOYSA-N [2-hydroxy-4-(2-hydroxyethoxy)phenyl]-phenylmethanone Chemical compound OC1=CC(OCCO)=CC=C1C(=O)C1=CC=CC=C1 SCMSRHIBVBIECI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 150000003926 acrylamides Chemical group 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005210 alkyl ammonium group Chemical group 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-M anthranilate Chemical class NC1=CC=CC=C1C([O-])=O RWZYAGGXGHYGMB-UHFFFAOYSA-M 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000004204 candelilla wax Substances 0.000 description 2
- 235000013868 candelilla wax Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940073669 ceteareth 20 Drugs 0.000 description 2
- 229940071160 cocoate Drugs 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- YHHHHJCAVQSFMJ-UHFFFAOYSA-N decadiene group Chemical group C=CC=CCCCCCC YHHHHJCAVQSFMJ-UHFFFAOYSA-N 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940031569 diisopropyl sebacate Drugs 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- DZTJRUYDMKJKPJ-UHFFFAOYSA-N ethane-1,2-diol;octadecanoic acid;propane-1,2,3-triol Chemical compound OCCO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O DZTJRUYDMKJKPJ-UHFFFAOYSA-N 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229960000192 felbinac Drugs 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002314 glycerols Chemical group 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- ZWVMLYRJXORSEP-UHFFFAOYSA-N hexane-1,2,6-triol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BFZNCPXNOGIELB-UHFFFAOYSA-N propan-2-yl 10-[5,6-dihexyl-2-(8-oxo-8-propan-2-yloxyoctyl)cyclohex-3-en-1-yl]dec-9-enoate Chemical compound CCCCCCC1C=CC(CCCCCCCC(=O)OC(C)C)C(C=CCCCCCCCC(=O)OC(C)C)C1CCCCCC BFZNCPXNOGIELB-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 239000008165 rice bran oil Substances 0.000 description 2
- 150000003902 salicylic acid esters Chemical class 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- 230000000261 vasodilator Effects 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- ILRKKHJEINIICQ-UFTZEXNXSA-N (2S,3S,4S,5R,6R)-6-[(3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carb Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](OC1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-UFTZEXNXSA-N 0.000 description 1
- ZNSIOEUWGZNHAQ-UHFFFAOYSA-N (3E)-N-diazoniopyridine-3-carboximidate Chemical compound [N-]=[N+]=NC(=O)C1=CC=CN=C1 ZNSIOEUWGZNHAQ-UHFFFAOYSA-N 0.000 description 1
- AQSGIPQBQYCRLQ-UHFFFAOYSA-N (6,6-dihydroxy-4-methoxycyclohexa-2,4-dien-1-yl)-phenylmethanone Chemical compound C1=CC(OC)=CC(O)(O)C1C(=O)C1=CC=CC=C1 AQSGIPQBQYCRLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-OIBJUYFYSA-N (S)-camphor Chemical compound C1C[C@]2(C)C(=O)C[C@H]1C2(C)C DSSYKIVIOFKYAU-OIBJUYFYSA-N 0.000 description 1
- QLLUAUADIMPKIH-UHFFFAOYSA-N 1,2-bis(ethenyl)naphthalene Chemical compound C1=CC=CC2=C(C=C)C(C=C)=CC=C21 QLLUAUADIMPKIH-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- MMEXPSCGRYPZKY-UHFFFAOYSA-N 1-(3-bromoindazol-2-yl)ethanone Chemical compound C1=CC=CC2=C(Br)N(C(=O)C)N=C21 MMEXPSCGRYPZKY-UHFFFAOYSA-N 0.000 description 1
- MWKFXSUHUHTGQN-UHFFFAOYSA-N 1-Decanol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- MMMPXNOKIZOWHM-UHFFFAOYSA-N 1-octoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCC MMMPXNOKIZOWHM-UHFFFAOYSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1-octoxyoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- FJCFFCXMEXZEIM-UHFFFAOYSA-N 1-oxidopyridin-1-ium-3-carboxylic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-M 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC([O-])=O XDOFQFKRPWOURC-UHFFFAOYSA-M 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- DRBARRGCABOUIE-UHFFFAOYSA-N 2,3-dihydroxy-3-phenylprop-2-enoic acid Chemical class OC(=O)C(O)=C(O)C1=CC=CC=C1 DRBARRGCABOUIE-UHFFFAOYSA-N 0.000 description 1
- WZPLEIAOQJXZJX-UHFFFAOYSA-N 2,3-dihydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C(O)=CC2=C1 WZPLEIAOQJXZJX-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- GUOJZFSYQUIYCN-OWOJBTEDSA-N 2,4,5-Trihydroxycinnamic acid Chemical class OC(=O)\C=C\C1=CC(O)=C(O)C=C1O GUOJZFSYQUIYCN-OWOJBTEDSA-N 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N 2-(11-oxo-6H-benzo[c][1]benzoxepin-2-yl)acetic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- PYIHCGFQQSKYBO-UHFFFAOYSA-N 2-(11-oxo-6H-benzo[c][1]benzoxepin-3-yl)acetic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 PYIHCGFQQSKYBO-UHFFFAOYSA-N 0.000 description 1
- MYQXHLQMZLTSDB-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OC(CC)CC2=C1 MYQXHLQMZLTSDB-UHFFFAOYSA-N 0.000 description 1
- BSWRKKZXYUISNO-UHFFFAOYSA-M 2-(2-ethylhexoxy)benzoate Chemical compound CCCCC(CC)COC1=CC=CC=C1C([O-])=O BSWRKKZXYUISNO-UHFFFAOYSA-M 0.000 description 1
- DUFKCOQISQKSAV-UHFFFAOYSA-N 2-(2-hydroxypropoxy)propan-1-ol Chemical compound CC(O)COC(C)CO DUFKCOQISQKSAV-UHFFFAOYSA-N 0.000 description 1
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-Methyl-2,4-pentanediol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- UCYLROVJSUACAD-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOCC(OCCO)COCCO UCYLROVJSUACAD-UHFFFAOYSA-N 0.000 description 1
- BGTZEQVWUZNMIY-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO BGTZEQVWUZNMIY-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- ZQZAHPFFZWEUCL-UHFFFAOYSA-N 2-chloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1Cl ZQZAHPFFZWEUCL-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- BSNJMDOYCPYHST-UHFFFAOYSA-N 2-ethenoxyethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC=C BSNJMDOYCPYHST-UHFFFAOYSA-N 0.000 description 1
- NBTXFNJPFOORGI-UHFFFAOYSA-N 2-ethenoxyethyl prop-2-enoate Chemical compound C=COCCOC(=O)C=C NBTXFNJPFOORGI-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N 2-hydroxy-5-(2-phenyl-4,5-dihydrobenzo[e]indol-3-yl)benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- IXIGWKNBFPKCCD-UHFFFAOYSA-N 2-hydroxy-5-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 IXIGWKNBFPKCCD-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- NEQXUPRFDXNNTA-UHFFFAOYSA-N 2-hydroxyethylazanium;2-hydroxypropanoate Chemical compound [NH3+]CCO.CC(O)C([O-])=O NEQXUPRFDXNNTA-UHFFFAOYSA-N 0.000 description 1
- ZVTDEEBSWIQAFJ-ZHACJKMWSA-N 2-hydroxypropyl (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(C)O ZVTDEEBSWIQAFJ-ZHACJKMWSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-M 2-hydroxystearate Chemical compound CCCCCCCCCCCCCCCCC(O)C([O-])=O KIHBGTRZFAVZRV-UHFFFAOYSA-M 0.000 description 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 2-methyl-1,3-oxazole Chemical compound CC1=NC=CO1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 1
- HTIVAHOAGNIWFV-UHFFFAOYSA-N 2-methyl-N-propan-2-ylprop-2-enamide;prop-2-enamide Chemical compound NC(=O)C=C.CC(C)NC(=O)C(C)=C HTIVAHOAGNIWFV-UHFFFAOYSA-N 0.000 description 1
- JCTNVNANPZAULC-UHFFFAOYSA-N 2-methylbenzo[e][1,3]benzoxazole Chemical compound C1=CC=C2C(N=C(O3)C)=C3C=CC2=C1 JCTNVNANPZAULC-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methylpentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 1
- PVRMECYYHAHLCP-UHFFFAOYSA-N 2-octadecanoyloxybutyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)OC(=O)CCCCCCCCCCCCCCCCC PVRMECYYHAHLCP-UHFFFAOYSA-N 0.000 description 1
- FIISKTXZUZBTRC-UHFFFAOYSA-N 2-phenyl-1,3-benzoxazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2O1 FIISKTXZUZBTRC-UHFFFAOYSA-N 0.000 description 1
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical class C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- WYKHFQKONWMWQM-UHFFFAOYSA-N 2-sulfanylidene-1H-pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1S WYKHFQKONWMWQM-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HMKKFLSUPRUBOO-IUPFWZBJSA-N 3,4-dihydroxy-5-[3,4,5-tris[[(Z)-octadec-9-enoyl]oxy]benzoyl]oxybenzoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(O)=O)O)=C1 HMKKFLSUPRUBOO-IUPFWZBJSA-N 0.000 description 1
- CNQCWYFDIQSALX-UHFFFAOYSA-N 3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 1
- USSFUVKEHXDAPM-UHFFFAOYSA-N 3-carbamoylpyridin-1-ium-1-olate Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 description 1
- AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 1
- OSMAGAVKVRGYGR-UHFFFAOYSA-N 3-methylpyridine-4-carboxylic acid Chemical compound CC1=CN=CC=C1C(O)=O OSMAGAVKVRGYGR-UHFFFAOYSA-N 0.000 description 1
- LGLDSEPDYUTBNZ-UHFFFAOYSA-N 3-phenylbuta-1,3-dien-2-ylbenzene Chemical compound C=1C=CC=CC=1C(=C)C(=C)C1=CC=CC=C1 LGLDSEPDYUTBNZ-UHFFFAOYSA-N 0.000 description 1
- VIESAWGOYVNHLV-UHFFFAOYSA-M 3H-pyrrol-2-olate Chemical class O=C1CC=C[N-]1 VIESAWGOYVNHLV-UHFFFAOYSA-M 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-O 4,5-dihydro-1H-imidazol-1-ium Chemical compound C1CN=C[NH2+]1 MTNDZQHUAFNZQY-UHFFFAOYSA-O 0.000 description 1
- OFVFGKQCUDMLLP-UHFFFAOYSA-N 4-(4,4-dimethyl-3-oxopentyl)-1,2-diphenylpyrazolidine-3,5-dione Chemical compound O=C1C(CCC(=O)C(C)(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 OFVFGKQCUDMLLP-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N 4-Methoxycinnamic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- STZSATRZAOXIOR-UHFFFAOYSA-N 4-amino-2,3-dimethyl-5-octylbenzoic acid Chemical compound CCCCCCCCC1=CC(C(O)=O)=C(C)C(C)=C1N STZSATRZAOXIOR-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-N-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- IBYCEACZVUOBIV-UHFFFAOYSA-N 4-methylpentyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCC(C)C IBYCEACZVUOBIV-UHFFFAOYSA-N 0.000 description 1
- AUGIYYGVQDZOLU-UHFFFAOYSA-N 4-methylpentyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCC(C)C AUGIYYGVQDZOLU-UHFFFAOYSA-N 0.000 description 1
- ZLWYEPMDOUQDBW-UHFFFAOYSA-N 6-aminonicotinamide Chemical compound NC(=O)C1=CC=C(N)N=C1 ZLWYEPMDOUQDBW-UHFFFAOYSA-N 0.000 description 1
- IJXDURUAYOKSIS-UHFFFAOYSA-N 6-methylpyridine-3-carboxamide Chemical compound CC1=CC=C(C(N)=O)C=N1 IJXDURUAYOKSIS-UHFFFAOYSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N 8-Hydroxyquinoline Chemical class C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 description 1
- 229940048299 ACETYLATED LANOLIN ALCOHOLS Drugs 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 102100017796 APP Human genes 0.000 description 1
- 108060000460 APP Proteins 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N AZAPROPAZONE Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N Aesculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- XHCADAYNFIFUHF-BGNCJLHMSA-N Aesculin Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-BGNCJLHMSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N Alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229950003408 Amcinafide Drugs 0.000 description 1
- 229940064734 Aminobenzoate Drugs 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N Ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- WMGFVAGNIYUEEP-WUYNJSITSA-N Amylopectin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]3[C@H](O[C@H](O)[C@H](O)[C@H]3O)CO)O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H]1O WMGFVAGNIYUEEP-WUYNJSITSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 229960000271 Arbutin Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N Avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229940090958 BEHENYL BEHENATE Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N Benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229940047187 Benzoresorcinol Drugs 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 229940083828 Bioflavonoid drugs for capillary stabilizing Drugs 0.000 description 1
- 229940093797 Bioflavonoids Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- ARUHDHLPYYESMA-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(=O)OC.CCCCCCCCCCCCCCCC(=O)OC(C)C Chemical compound CCCCCCCCCCCCCCCC(=O)OC.CCCCCCCCCCCCCCCC(=O)OC(C)C ARUHDHLPYYESMA-UHFFFAOYSA-N 0.000 description 1
- DLQDPUCZIABCES-VZBBZXSKSA-N CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)C=O Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)C=O DLQDPUCZIABCES-VZBBZXSKSA-N 0.000 description 1
- 229940073639 CETEARETH-6 Drugs 0.000 description 1
- SXVBHNXTPNLOKR-FCLWLKJISA-L Calcium alginate Chemical compound [Ca+2].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O SXVBHNXTPNLOKR-FCLWLKJISA-L 0.000 description 1
- 229940073532 Candelilla Wax Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229960004203 Carnitine Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229940119217 Chamomile extract Drugs 0.000 description 1
- NPSLCOWKFFNQKK-ZPSUVKRCSA-N Chloroprednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](Cl)C2=C1 NPSLCOWKFFNQKK-ZPSUVKRCSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 240000007170 Cocos nucifera Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 240000001644 Cola acuminata Species 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 241000159174 Commiphora Species 0.000 description 1
- 240000003890 Commiphora wightii Species 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 240000005497 Cyamopsis tetragonoloba Species 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229940099371 DIACETYLATED MONOGLYCERIDES Drugs 0.000 description 1
- 229940031766 DIETHANOLAMINE CETYL PHOSPHATE Drugs 0.000 description 1
- HOIXTKAYCMNVMY-PVOAASPHSA-N Daphnin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=CC(=O)O2)C2=C1O HOIXTKAYCMNVMY-PVOAASPHSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N Desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 Desoximetasone Drugs 0.000 description 1
- 229960004486 Desoxycorticosterone acetate Drugs 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004833 Dexamethasone phosphate Drugs 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N Dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N Dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- FVCOIAYSJZGECG-UHFFFAOYSA-N Diethylhydroxylamine Chemical compound CCN(O)CC FVCOIAYSJZGECG-UHFFFAOYSA-N 0.000 description 1
- 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Difluocortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- VJHINFRRDQUWOJ-UHFFFAOYSA-N Dioctyl sebacate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC(=O)OCC(CC)CCCC VJHINFRRDQUWOJ-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N Dioxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- 229940101029 Dipotassium Glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N Dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940105576 Disalcid Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N Dodecanol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelide Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940093496 Esculin Drugs 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229950006236 Fenclofenac Drugs 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N Fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950005416 Fendosal Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229960003973 Fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N Fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N Fluprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- 229960000618 Fluprednisolone Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229950010931 Furofenac Drugs 0.000 description 1
- 229940087559 GRAPE SEED Drugs 0.000 description 1
- 229940074391 Gallic acid Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229940015043 Glyoxal Drugs 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 1
- 210000003780 Hair Follicle Anatomy 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N Hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N Herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N Hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N Hexadecyl Octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- FWFVLWGEFDIZMJ-FOMYWIRZSA-N Hydrocortamate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CN(CC)CC)(O)[C@@]1(C)C[C@@H]2O FWFVLWGEFDIZMJ-FOMYWIRZSA-N 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N Hydrocortisone 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone cypionate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCC1CCCC1 DLVOSEUFIRPIRM-KAQKJVHQSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229940054190 Hydroxypropyl Chitosan Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000000069 Hyperpigmentation Diseases 0.000 description 1
- 229940093629 ISOPROPYL ISOSTEARATE Drugs 0.000 description 1
- 229940089456 ISOPROPYL STEARATE Drugs 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N Indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N Inositol nicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 229960005436 Inositol nicotinate Drugs 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N Isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- 229950011455 Isoxepac Drugs 0.000 description 1
- 210000001847 Jaw Anatomy 0.000 description 1
- 229940039371 Karaya Gum Drugs 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229940031674 LAURETH-7 Drugs 0.000 description 1
- 229940069445 LICORICE EXTRACT Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229940010454 Licorice Drugs 0.000 description 1
- 210000000088 Lip Anatomy 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940078555 MYRISTYL PROPIONATE Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N Meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001139947 Mida Species 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N Miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 229950006616 Miroprofen Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WFKDPJRCBCBQNT-UHFFFAOYSA-N N,2-dimethylprop-2-enamide Chemical compound CNC(=O)C(C)=C WFKDPJRCBCBQNT-UHFFFAOYSA-N 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N N,N'-Methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- QRWZCJXEAOZAAW-UHFFFAOYSA-N N,N,2-trimethylprop-2-enamide Chemical compound CN(C)C(=O)C(C)=C QRWZCJXEAOZAAW-UHFFFAOYSA-N 0.000 description 1
- 229940088644 N,N-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N N,N-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- JRFKIOFLCXKVOT-UHFFFAOYSA-N N-(hydroxymethyl)pyridine-3-carboxamide Chemical compound OCNC(=O)C1=CC=CN=C1 JRFKIOFLCXKVOT-UHFFFAOYSA-N 0.000 description 1
- JIAOUYONZMRJJD-UHFFFAOYSA-N N-benzylpyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCC1=CC=CC=C1 JIAOUYONZMRJJD-UHFFFAOYSA-N 0.000 description 1
- ZXOAHASJYIUCBG-UHFFFAOYSA-N N-ethylpyridine-3-carboxamide Chemical compound CCNC(=O)C1=CC=CN=C1 ZXOAHASJYIUCBG-UHFFFAOYSA-N 0.000 description 1
- NYQXIOZBHWFCBU-UHFFFAOYSA-N N-phenylpyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC1=CC=CC=C1 NYQXIOZBHWFCBU-UHFFFAOYSA-N 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N N-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N Nialamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 229960003057 Nialamide Drugs 0.000 description 1
- RSKQGBFMNPDPLR-UHFFFAOYSA-N Niaprazine Chemical compound C=1C=CN=CC=1C(=O)NC(C)CCN(CC1)CCN1C1=CC=C(F)C=C1 RSKQGBFMNPDPLR-UHFFFAOYSA-N 0.000 description 1
- 229960004738 Nicotinyl Alcohol Drugs 0.000 description 1
- ZYVXHFWBYUDDBM-UHFFFAOYSA-N Nicotinyl methylamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 description 1
- BRZANEXCSZCZCI-UHFFFAOYSA-N Nifenazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C)C(C)=C1NC(=O)C1=CC=CN=C1 BRZANEXCSZCZCI-UHFFFAOYSA-N 0.000 description 1
- UAYFVMHNRVWNLL-UHFFFAOYSA-M OCNCC(=O)O.[Na+].[Cl-] Chemical compound OCNCC(=O)O.[Na+].[Cl-] UAYFVMHNRVWNLL-UHFFFAOYSA-M 0.000 description 1
- URSCRKIYUPROKB-PHHCKKAISA-N OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O URSCRKIYUPROKB-PHHCKKAISA-N 0.000 description 1
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N Octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 1
- 229950002083 Octabenzone Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229950005708 Oxepinac Drugs 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N Oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 229940072880 PEG-10 STEARATE Drugs 0.000 description 1
- 229940077414 PEG-12 STEARATE Drugs 0.000 description 1
- 229940119517 PEG-6 STEARATE Drugs 0.000 description 1
- 229940100518 POLYGLYCERYL-4 ISOSTEARATE Drugs 0.000 description 1
- 229940113171 POLYSORBATE 85 Drugs 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 229940101267 Panthenol Drugs 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229960005235 Piperonyl Butoxide Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N Pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L Potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 229940043131 Pyroglutamate Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 229940093918 Quinoline gynecological antiinfectives Drugs 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N Quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-N Ricinoleic acid Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-QJWNTBNXSA-N 0.000 description 1
- WBHHMMIMDMUBKC-GKUQOKNUSA-N Ricinoleic acid Natural products CCCCCC[C@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-GKUQOKNUSA-N 0.000 description 1
- 241001103643 Rubia Species 0.000 description 1
- 240000009235 Rubia cordifolia Species 0.000 description 1
- 229940100459 STEARETH-20 Drugs 0.000 description 1
- 229940100458 STEARETH-21 Drugs 0.000 description 1
- 229950005175 SUDOXICAM Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 210000004761 Scalp Anatomy 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 210000001732 Sebaceous Glands Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N Silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004029 Silicic Acid Drugs 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229940010747 Sodium Hyaluronate Drugs 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 229950011392 Sorbitan stearate Drugs 0.000 description 1
- 229940033331 Soy Sterol Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940031439 Squalene Drugs 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N Sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide Dismutase Proteins 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 210000000106 Sweat Glands Anatomy 0.000 description 1
- 229960000716 TONICS Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229940033123 Tannic Acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N Tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000009056 Telangiectasis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940042585 Tocopherol Acetate Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N Tolfenamic acid Chemical class CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 Triamcinolone Acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229940078279 Trilisate Drugs 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 229940116269 Uric Acid Drugs 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- 229950007802 Zidometacin Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N Zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- HHPZZKDXAFJLOH-QZIXMDIESA-N [(2S)-1-[(8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-1-oxopropan-2-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 description 1
- GYNAYXFRCBVFOE-XBZOGAIXSA-J [(2S,3R,4S,6S)-2-[(2R,3S,4R,5R,6S)-6-[(2S,3R,4R,5R)-3,4-dihydroxy-5-[(2R,3R,4R,5R,6R)-6-hydroxy-2-(hydroxymethyl)-4,5-disulfonatooxyoxan-3-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-6-(sulfonatooxymethyl)oxan-3-yl] sulfate Chemical compound O([C@@H]1CO[C@H]([C@@H]([C@H]1O)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)C[C@@H](COS([O-])(=O)=O)O1)OS([O-])(=O)=O)CO)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](OS([O-])(=O)=O)[C@@H]1OS([O-])(=O)=O GYNAYXFRCBVFOE-XBZOGAIXSA-J 0.000 description 1
- VYGQUTWHTHXGQB-YFAKFODJSA-N [(2Z,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-YFAKFODJSA-N 0.000 description 1
- YYDZACXIVKPEAI-ZPHPHTNESA-N [(Z)-octadec-9-enyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC YYDZACXIVKPEAI-ZPHPHTNESA-N 0.000 description 1
- WMOBLRURFXZUMY-MSUUIHNZSA-N [(Z)-octadec-9-enyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC WMOBLRURFXZUMY-MSUUIHNZSA-N 0.000 description 1
- HVUMOYIDDBPOLL-IIZJTUPISA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O HVUMOYIDDBPOLL-IIZJTUPISA-N 0.000 description 1
- DEFOZIFYUBUHHU-IYQKUMFPSA-N [2-[(8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-16-methylidene-3-oxo-7,8,11,12,14,15-hexahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O DEFOZIFYUBUHHU-IYQKUMFPSA-N 0.000 description 1
- VRAHPESAMYMDQI-UHFFFAOYSA-N [2-hydroxy-1,3,3-tris(pyridine-3-carbonyloxymethyl)cyclohexyl]methyl pyridine-3-carboxylate Chemical compound C1CCC(COC(=O)C=2C=NC=CC=2)(COC(=O)C=2C=NC=CC=2)C(O)C1(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 VRAHPESAMYMDQI-UHFFFAOYSA-N 0.000 description 1
- PNTLMFABGCHLMN-UHFFFAOYSA-N [4-(2-hydroxyethoxy)phenyl]-phenylmethanone Chemical compound C1=CC(OCCO)=CC=C1C(=O)C1=CC=CC=C1 PNTLMFABGCHLMN-UHFFFAOYSA-N 0.000 description 1
- BLNXQXNMBAGIHY-UHFFFAOYSA-L [O-]S(=O)(=O)C1=C(S([O-])(=O)=O)C(O)=CC=C1C1=CC=CC=C1 Chemical class [O-]S(=O)(=O)C1=C(S([O-])(=O)=O)C(O)=CC=C1C1=CC=CC=C1 BLNXQXNMBAGIHY-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- DHFCLYNGVLPKPK-UHFFFAOYSA-N acetamide;2-aminoethanol Chemical compound CC(N)=O.NCCO DHFCLYNGVLPKPK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N acrylaldehyde Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- XXXHSQBVHSJQKS-UHFFFAOYSA-N amino benzoate Chemical compound NOC(=O)C1=CC=CC=C1 XXXHSQBVHSJQKS-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000003356 anti-rheumatic Effects 0.000 description 1
- 230000001153 anti-wrinkle Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drugs Fenamates Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drugs Oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic products Propionic acid derivatives Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940027991 antiseptics and disinfectants Quinoline derivatives Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001479 arabinose derivatives Chemical class 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- ROPXFXOUUANXRR-YPKPFQOOSA-N bis(2-ethylhexyl) (Z)-but-2-enedioate Chemical compound CCCCC(CC)COC(=O)\C=C/C(=O)OCC(CC)CCCC ROPXFXOUUANXRR-YPKPFQOOSA-N 0.000 description 1
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 1
- IUGNTDSUZLPSOK-UHFFFAOYSA-N bis(4-methylpentyl) hexanedioate Chemical compound CC(C)CCCOC(=O)CCCCC(=O)OCCCC(C)C IUGNTDSUZLPSOK-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- 229930000006 bisabolols Natural products 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- RYWRRSGRSLDCCX-UHFFFAOYSA-N butane-1,2-diol;octadecanoic acid Chemical compound CCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O RYWRRSGRSLDCCX-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229930007890 camphor Natural products 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229950006229 chloroprednisone Drugs 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- WJMQFZCWOFLFCI-UHFFFAOYSA-N cyanomethyl prop-2-enoate Chemical compound C=CC(=O)OCC#N WJMQFZCWOFLFCI-UHFFFAOYSA-N 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KBODESQIOVVMAI-UHFFFAOYSA-N decyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCC KBODESQIOVVMAI-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- VLNBQUAHERCLKT-UHFFFAOYSA-N dimethylamino benzoate Chemical compound CN(C)OC(=O)C1=CC=CC=C1 VLNBQUAHERCLKT-UHFFFAOYSA-N 0.000 description 1
- TVWTZAGVNBPXHU-NXVVXOECSA-N dioctyl (Z)-but-2-enedioate Chemical compound CCCCCCCCOC(=O)\C=C/C(=O)OCCCCCCCC TVWTZAGVNBPXHU-NXVVXOECSA-N 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 1
- NJIMZDGGLTUCPX-UHFFFAOYSA-N docosyl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCCCCCC NJIMZDGGLTUCPX-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- IAJNXBNRYMEYAZ-UHFFFAOYSA-N ethyl 2-cyano-3,3-diphenylprop-2-enoate Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC)C1=CC=CC=C1 IAJNXBNRYMEYAZ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940094766 flucloronide Drugs 0.000 description 1
- 229950009938 flumetasone pivalate Drugs 0.000 description 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960003590 fluperolone Drugs 0.000 description 1
- 229960002650 fluprednidene acetate Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic Secondary and tertiary amines Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-K glycyrrhizinate(3-) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C([O-])=O)C)(C)CC2)(C)CC1)(C)C)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-K 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- WUKXMJCZWYUIRZ-UHFFFAOYSA-N hexadecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(C)O WUKXMJCZWYUIRZ-UHFFFAOYSA-N 0.000 description 1
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-L hexadecyl phosphate Chemical compound CCCCCCCCCCCCCCCCOP([O-])([O-])=O ZUVCYFMOHFTGDM-UHFFFAOYSA-L 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical class [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229950000208 hydrocortamate Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960003331 hydrocortisone cypionate Drugs 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000005165 hydroxybenzoic acids Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 231100001006 hyperpigmentation Toxicity 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 229950004594 levomenol Drugs 0.000 description 1
- 235000014063 licorice root Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 125000005644 linolenyl group Chemical group 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- KDQIFKKWPMBNOH-UHFFFAOYSA-N methyl 16-methylheptadecanoate Chemical compound COC(=O)CCCCCCCCCCCCCCC(C)C KDQIFKKWPMBNOH-UHFFFAOYSA-N 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960002686 niaprazine Drugs 0.000 description 1
- 229950001071 nicomol Drugs 0.000 description 1
- 229960002187 nifenazone Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- CMCJFUXWBBHIIL-UHFFFAOYSA-N octadecanoic acid;propane-1,2-diol Chemical class CC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CMCJFUXWBBHIIL-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-M palmitoleate Chemical compound CCCCCC\C=C/CCCCCCCC([O-])=O SECPZKHBENQXJG-FPLPWBNLSA-M 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940096994 peg-10 glyceryl stearate Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- QTECDUFMBMSHKR-UHFFFAOYSA-N prop-2-enyl prop-2-enoate Chemical compound C=CCOC(=O)C=C QTECDUFMBMSHKR-UHFFFAOYSA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- PWHUPFOHNXWYSH-UHFFFAOYSA-N pyridin-3-ylmethylurea Chemical compound NC(=O)NCC1=CC=CN=C1 PWHUPFOHNXWYSH-UHFFFAOYSA-N 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- XQWBMZWDJAZPPX-UHFFFAOYSA-N pyridine-3-carbothioamide Chemical compound NC(=S)C1=CC=CN=C1 XQWBMZWDJAZPPX-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001603 reducing Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000037335 skin penetration Effects 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(Z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 229940010735 steareth-12 Drugs 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- DIORMHZUUKOISG-UHFFFAOYSA-M sulfoformate Chemical compound OC(=O)S([O-])(=O)=O DIORMHZUUKOISG-UHFFFAOYSA-M 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 231100001005 telangiectasia Toxicity 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 230000001256 tonic Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 229940026752 topical Sulfonamides Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 229950000919 tribuzone Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
Abstract
Disclosed are skin care compositions containing retinoids which generally improve the quality of the skin, particularly human facial skin. More particularly, the present invention relates to retinol containing skin care compositions with improved skin compatiblity.
Description
COMPOSITIONS OF SKIN CARE
TECHNICAL FIELD
The invention relates to skin care compositions containing retinoids that generally improve the quality of the skin, particularly the human facial skin. More particularly, the present invention relates to skin care compositions containing retinol with improved skin compatibility.
BACKGROUND OF THE INVENTION
Several personal care products that are currently available to consumers are primarily aimed at improving the health and / or physical appearance of the skin. Among such skin care products, several are aimed at delaying, minimizing or even eliminating wrinkles of the skin and other histological changes typically associated with skin age or environmental damage to human skin. The skin is subjected to adversity by various extrinsic and intrinsic factors. Extrinsic factors include ultraviolet radiation (ie, sun exposure), environmental pollution, wind, heat, low humidity, harsh surfactants, abrasives, and the like. Intrinsic factors include chronological aging and other changes
biochemicals within the skin. Whether extrinsic or intrinsic, these factors result in visible signs of skin aging and environmental damage, such as wrinkling and other forms of roughness (including increased pore size, detachment and skin lines), and other associated histological changes with aging or skin damage. For several people, wrinkles on the skin are a reminder of the disappearance of youth. As a result, the elimination of wrinkles has become a good business in societies that are aware of youth. The treatments vary from creams and cosmetic moisturizers to various forms of cosmetic surgery. Extrinsic or intrinsic factors can result in thinning and general degradation of the skin. For example, as the skin ages, there is a reduction in the cells and blood vessels that supply the skin. There is also a flattening of the dermal / epidermal junction that results in a weaker mechanical strength of said junction. See, for example, Oikarinen, "The Aging of Skin: Chronoaging Versus Photoaging", Photodermatol, Photoimmunol. Photomed., Vol 7, pp. 3-4. 1990, which is incorporated by reference herein in its entirety. Retinoids are recognized as anti-wrinkle assets that help reduce the subcutaneous effects of aging such as wrinkles, peeling, loosening, roughness, dryness and spots (hyperpigmentation) (see U.S. Patents 4,603,146 and 4,877,805 to Kligman). It has been postulated that retinoids act through production
of inflammation, which causes thickening of the epidermis (acanthosis), and local intracellular edema, leading to exfoliation. In formulation products containing retinoids, much of the attention is directed to providing compositions that provide and retain optimal retinoid concentrations in the stratum corneum with minimal absorption in the systemic circulation. In addition, the promotion of user acceptance with respect to chronic treatment regimens is also important. Current retinoid formulations, however, can be drying and irritating and result in excessive peeling. Such formulations can cause individuals to refrain from using retinoid products as often and as necessary for optimum benefit. The present inventors have found that compositions containing natural or synthetic retinoid compounds together with a preservative component comprising a formaldehyde donor preservative and a halogenopropynyl compound, provide the skin regulating benefits of retinoid compounds with dryness and / or reduced irritation. Said compositions have improved the acceptance of the user and, in this way, promote a better acceptance of the user with a concomitant overall improvement in the skin's regulatory benefit. Therefore, it is an object of the present invention to provide skin care compositions containing retinoid and having improved skin compatibility.
Another object of the present invention is to provide retinoid compositions containing preservative systems that provide conservation activity at relatively low concentrations. It is still another object of the present invention to provide retinoid compositions containing preservative systems that do not substantially impact the stability or bioavailability of the retinoid. These and other objects of the present invention will become apparent in the light of the following description.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to skin care compositions, comprising: (a) a retinoid; and (b) a preservative component, comprising: (i) a formaldehyde donor; and (ii) a halogenopropynyl compound selected from the group consisting of iodopropalgyl esters, ethers, acetals, carbamates and carbonates. The present invention also relates to methods of regulating skin conditioning.
DETAILED DESCRIPTION OF THE INVENTION
All percentages and ratios used herein are by weight of the total composition, and all measurements were made at 25 ° C, unless otherwise indicated. The compositions of the present invention may comprise, consist essentially of, or consist of, the essential ingredients, as well as other ingredients and optional components described herein. As used herein, the phrase "consists essentially of" refers to the fact that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods. All publications cited herein are incorporated by reference in their entirety. The term "topical application", as used herein, refers to the application or spreading of the compositions of the present invention on the surface of the skin. The term "dermatologically acceptable", as used herein, means that the compositions or components thereof described herein are suitable for use in contact with human skin without undue toxicity, incompatibility, instability, allergic response and Similar.
The term "safe and effective amount", as used herein, refers to an amount of a compound, component or composition sufficient to induce significantly a positive benefit, preferably an appearance or benefit of positive skin sensations, including independently to the benefits described herein, but low enough to avoid serious side effects, that is, to provide a reasonable benefit to the risk relationship, within the reach of the judgment of the person skilled in the art. The term "skin compatibility", as used herein, refers to the ability of the skin to tolerate application over a long period of topical compositions with minimal adverse reactions to the skin, such as swelling, burns, reddish character, sting and folliculitis. The compositions of the present invention are useful for topical application and for regulating the condition of the skin, including visible and / or tactile discontinuities in the skin (especially to the surface of the skin, said discontinuities generally being undesirable). Such discontinuities may be induced or caused by internal and / or external factors, and include the signs of skin aging described herein. The term "regulation of the condition of the skin" includes the prophylactic regulation and / or therapeutic regulation of the condition of the skin, including visible and / or tactile discontinuities in the skin. As used herein, the prophylactic regulation of skin condition includes the
delay, minimization and / or prevention of visible and / or tactile discontinuities in the skin. As used in this, the therapeutic regulation condition of the skin includes the improvement, for example, decrease, minimization and / or elimination of discontinuities in the skin. The regulation of the condition of the skin involves the improvement of the appearance and / or sensation of the skin. The compositions of the present invention are useful for regulating the signs of skin aging, more specifically the visible and / or tactile discontinuities in the skin texture associated with aging. "Regulation of the signs of skin aging" includes the prophylactic regulation and / or therapeutic regulation of one or more of said signs (similarly, the regulation of a given sign of skin aging, i.e., lines, wrinkles or pores, includes the prophylactic regulation and / or therapeutic regulation of said signal). As used herein, prophylactic regulation of such signs includes delaying, minimizing and / or preventing the signs of skin aging. As used herein, therapeutic regulation of such signs includes improvement, for example, decrease, minimization and / or elimination of the signs of skin aging. The "signs of skin aging" include, but are not limited to, all visible and tactilely perceptible manifestations to the exterior, as well as to any of the other macro or microefects caused by the aging of the skin. These signs can be induced or caused
by intrinsic factors or extrinsic factors, for example, chronological aging and / or environmental damage. These signs may originate from processes that include, but are not limited to, the development of texture discontinuities such as wrinkles, including both fine surface wrinkles and deep deep wrinkles, skin lines, folds, bulges, large pores (e.g. , associated with attached structures such as sweat gland ducts, sebaceous glands or hair follicles), dryness, scaly and / or other forms of disuniformity or roughness of the skin, loss of skin elasticity (loss and / or inactivation of the skin). functional elastin in the skin), sagging (including swelling in the eye and jaw area), loss of skin firmness, loss of skin stiffness, loss of skin recovery from deformation, discoloration (including circles under the eye), redness, paleness, hyperpigmented regions on the skin such as spots and freckles due to age, keratoses, differentiation abnormal, hyperkeratinization, elastosis, collagen degradation and other histological changes in the stratum corneum, dermis, epidermis, the vascular system of the skin (eg, telangiectasia or spider vessels), and underlying tissues, especially those close to the skin. It should be understood that the present invention is not limited to the regulation of the "signs of skin aging" mentioned above, which originate due to mechanisms associated with the aging of the skin, but it is intended to include the regulation of said
signs regardless of the mechanism of origin. As used herein, the phrase "regulate the condition of the skin" is intended to include the regulation of such signs regardless of their mechanism of origin. The present invention is especially useful for therapeutically regulating visible and / or tactile discontinuities in the texture of mammalian skin, including discontinuities in texture related to skin aging. As used herein, the therapeutic regulation of said discontinuities includes the improvement, for example, decrease, minimization and / or fading of the visible and / or tactile discontinuities of the skin of a mammal, to thereby provide an appearance and / or improved skin sensation; for example, a smoother, more uniform appearance and / or feel. Said visible and / or tactile discontinuities in the texture of the skin include cracks, protuberances, pores, thin lines, wrinkles, peels, scales and / or other forms of unevenness or roughness in the texture associated with the aging of the skin. For example, the length, depth and / or other dimension of the lines and / or wrinkles decrease, the apparent diameter of the pores decreases, or the apparent height of the tissue immediately close to the openings of the pores approaches that of the skin. interanexa. The present invention is also especially useful for prophylactically regulating visible and / or tactile discontinuities in the texture of a mammalian skin, including texture discontinuities associated with skin aging. As used in the present, regulation
prophylactic of said discontinuities includes the delay, minimization and / or prevention of visible and / or tactile discontinuities in the texture of the skin of a mammal, to thereby provide improved appearance and / or sensation of the skin, for example, a appearance and / or even softer feeling.
ESSENTIAL COMPONENTS
Retinoid component A retinoid or retonoid as a compound is essential for the compositions of the present invention. As used herein, "retinoid" includes all natural and / or synthetic analogs of vitamin A or retinol-like compounds that possess the biological activity of vitamin A in the skin as well as geometric isomers and stereoisomers of said compounds The retinoid is preferably retinol, retinol esters (for example alkyl esters of C2-C22 retinol, including retinyl palmitate, retinyl acetate, retinyl proprionate), retinal, and / or retinoic acid (including all-trans retinoic acid and / or 13- cis-retinoic acid), more preferably retinoids other than retinoic acid. Such compounds are well known in the art and are commercially available from a number of sources, for example, Sigma Chemical Company (St. Louis, MO) and Boerhinger Mannheim (Indianapolis, IN). Other retinoids that are useful herein are described in U.S. Pat. Nos. 4,677,120,
issued on June 30, 1987 to Parish et al; 4,885,311, issued December 5, 1989 to Parish et al; 5,049,584, issued September 17, 1991 to Purcell et al; 5,124,356, issued June 23, 1992 to Purcell et al; and reissue 34,075, issued September 22, 1992 to Purcell et al. Other suitable retinoids are tocopheryl retinoate [tocopheryl ester of retinoic acid (trans- or cis-), adapalene. { 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid} . and tazarotene (ethyl 6- [2- (4,4-dimethylthiochroman-6-yl) -etinyl] nicotinate). One or more retiniodes can be used in the present. Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, retinyl propionate, retinal and combinations thereof. The most preferred are retinol and retinyl palmitate. The retinoid can be included as a substantially pure material, or as an extract obtained by physical and / or chemical isolation from natural sources (e.g., plants). The retinoid is preferably substantially pure, more preferably essentially pure. The compositions of the present invention contain a safe and effective amount of the retinoid to regulate the condition of the skin, preferably to regulate visible and / or tactile discontinuities in the skin, more preferably to regulate the signs of skin aging, yet more preferably to regulate visible and / or tactile discontinuities in the skin texture associated with skin aging. The compositions preferably contain from about 0.005% to about 2%, more preferably from 0.01% to about 2% retinoid. He
Retinol is most preferably used in an amount of from about 0.01% to about 0.15%; the retinol esters are more preferably used in an amount of from about 0.01% to about 2% (e.g., about 1%); the retinoic acids are more preferably used in an amount of from about 0.01% to about 0.25%; tocopheryl retinoate [tocopherol ester of retinoic acid (trans- or cis), adapalene. { 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid} , and tazarotene are more preferably used in an amount of from about 0.01% to about 2%. When the composition contains a retinoid, the vitamin B3 compound is preferably used in an amount of from about 0.1% to about 10%, more preferably from about 2% to about 5%.
Conservative Component Also essential for the compositions of the present invention is a preservative component comprising a formaldehyde donor and a halogenopropynyl compound. The preservative component of the present invention provides a substantially non-negative impact for the stability of the active ingredient. The phrase "substantially non-negative impact", as used herein, means that less than about 10% of the active is chemically degraded or otherwise altered resulting in an inactive degradation product when in the presence of the preservative component in the composition herein for a period of one month at a temperature of 40 ° C.
Suitable pharmachaldehyde donors have chemical and physical characteristics compatible with the use of personal care products. Said products preferably are not odoriferous, irritant or toxic when applied to the skin. Examples of suitable formaldehyde donors include dimethyloldimethylhydonate, N, N "-methylenebis [N '- [hydroxymethyl) -2,5-dioxo-4-imidazolidinyl] urea]; N- (hydroxymethyl) -N- (1,3-d) Hydroxymethyl-2,5-dioxo-4-imidazolidinyl) -N-hydroxymethyl) urea, the cis isomer of sodium chloride hydroxymethylglycinate 1- (3-chloroalyl) -3,5,7-triaza-1 -azoaniadamantane, di methyloxazole, 7-ethylbicycloxasolidine, 2-bromo-2-nitropropan-1,3-diol, 5-bromo-5-nitro-1,3-dioxane and mixtures thereof Examples of halogenopropynyl compounds suitable include compounds derived from propargyl or iodopropargyl alcohols such as esters, ethers, acetals, carbamates and carbonates and the iodopropargyl derivatives of pyrimidines, triazolinones, tetrazoles, triazinones, sulfonamides, benzothiazoles, ammonium salts, carboxamides, hydroxyamates, ureas and mixtures thereof. Preferred among said compounds is 3-iodo-2-propynylbutylcarbamate (IPBC). Said compound is included in the widely useful class of compounds having the generic formula:
wherein R is selected from the group consisting of substituted and unsubstituted alkyl, aryl and alkylaryl groups having from 1 to 20 carbon atoms, and m and n are independently integers from 1 to 3. The weight ratio of the two components varies depending on the application and the particular component selected. More broadly, the weight ratio varies from about 2000: 1 to about 1: 1 parts of the first to second component that can be used, preferably from about 500: 1 to about 1: 1, more preferably from about 200: 1 to about 1: 1, the parts being by weight. The preservative component of the present invention is present at a concentration of about 0.001% to about 5%, preferably from about 0.01% to about 3%, more preferably from about 0.01% to about 2%, more preferably from about 0.05% to about 1% and more preferably from about 0.05% to about 0.2%.
OPTIONAL COMPONENTS
Vehicle The compositions of the present invention comprise from about 1% to about 99.5% of a dermatologically acceptable vehicle within which are incorporated the essential retinoid and the preservative component and other optional materials, to enable the optional components to be provided to the skin at a concentration
adequate The vehicle can then act as a diluent, dispersant, solvent or the like for the particulate material, which ensures that it can be applied and evenly distributed over the selected target area at a suitable concentration. The vehicle may contain one or more fillers, diluents, solvents, extenders and the like, solids, semisolids or dermatologically acceptable liquids. The vehicle can be solid, semi-solid or liquid. The vehicles that are preferred are substantially liquid. The vehicle can itself be inert or it can have its own dermatological benefits. Vehicle concentrations may vary with the selected vehicle and the desired concentrations of the essential and optional components. Suitable vehicles include conventional vehicles and other known vehicles that are dermatologically acceptable. The vehicle must also be physically and chemically compatible with the essential components described herein, and must not unduly impair the stability, efficacy or other benefits of use associated with the compositions of the present invention. The preferred components of the compositions of the present invention should be capable of combining such that there is no interaction that would substantially reduce the effectiveness of the composition under normal use situations.
The type of vehicle used in the present invention depends on the type of product form desired for the composition. Topical compositions useful in the present invention can be made in a variety of product forms such as those known in the art. These include, but are not limited to, lotions, creams, gels, bars, sprays, ointments, pastes, mousses and cosmetics (for example, solid, semi-solid or liquid makeup, including foundation, eye makeup, pigmented lip treatments or not). pigmented, for example, lipsticks, and the like). These product forms can comprise various types of vehicles including, but not limited to, solutions, aerosols, emulsions, gels, solids and liposomes. Preferred carriers contain a dermatologically acceptable hydrophilic diluent. As used herein, "diluent" includes materials in which the particulate material may be dispersed, dissolved or otherwise incorporated. Non-limiting examples of hydrophilic diluents are water, organic hydrophilic diluents such as lower monovalent alcohols (e.g., C C4) and low molecular weight polyols and glycols, including propylene glycol, polyethylene glycol (e.g., molecular weight 200-600 g / mole) ), polypropylene glycol (for example, molecular weight of 425-2025 g / mole), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters, 1, 2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, propanolic ether, ethoxylated ethers, propoxylated ethers and combinations of
the same. Water is a preferred diluent. The composition preferably comprises from about 60% to about 99.99% of the hydrophilic diluent. Solutions according to the present invention typically include a dermatologically acceptable hydrophilic diluent. The solutions useful in the present invention preferably contain from about 60% to about 99.99% of the hydrophilic diluent. The aerosols according to the present invention can be formed by adding a propellant to a solution as described above. Exemplary propellants include chloro-fluorinated hydrocarbons of low molecular weight. Additional propellants that are useful herein are described in Sagarin, Cosmetics Science and Technology. 2nd edition. Vol. 2, pp. 443-465 (1972), incorporated herein by reference. Aerosols are typically applied to the skin as a spray product. Preferred carriers comprise an emulsion consisting of a hydrophilic phase comprising a hydrophilic component, for example, water or another hydrophilic diluent, and a hydrophobic phase comprising a hydrophobic component, for example, a lipid, oil or oily material. As is well known to the person skilled in the art, the hydrophobic phase will be dispersed in the hydrophobic phase, or vice versa, to form dispersed and continuous hydrophilic or hydrophobic phases respectively, depending on the ingredients of the composition. In emulsion technology, the term "dispersed phase" is a well-known term for a
skilled in the art, and means that the phase exists as small particles or droplets that are suspended in, and surrounded by, a continuous phase. The dispersed phase is also known as the internal or discontinuous phase. The emulsion may be or comprise (for example, in a three-phase or multi-phase emulsion) an oil-in-water emulsion or a water-in-oil emulsion such as a water-in-silicone emulsion. The oil-in-water emulsions typically comprise from about 1% to about 50% of the hydrophobic dispersed phase, and from about 1% to about 98% of the continuous hydrophilic phase; Water-in-oil emulsions typically comprise from about 1% to about 98% of the dispersed hydrophilic phase, and from about 1% to about 50% of the continuous hydrophobic phase. The emulsion may also comprise a gel network, such as that described in G.M. Eccleston, "Application of Emulsion Stability Theories to Mobile and Semisolid O / W Emulsions", Cosmetics & Toiletries. Vol. 101, November 1986, pp. 73-92, incorporated herein by reference. Preferred emulsions are described further below. The topical compositions of the present invention, including but not limited to, lotions and creams, may comprise a dermatologically acceptable emollient. Said compositions preferably contain from about 2% to about 50% of the emollient. Emollients tend to lubricate the skin, increase the smoothness and smoothness of the skin, prevent or relieve the dryness of the skin and / or protect the skin. Emollients are typically oily or waxy materials not miscible in
Water. A wide variety of suitable emollients are known and can be used herein. Sagarin, Cosmetics, Science and Technology, 2nd edition, vol. 1, pp. 32-43 (1972), incorporated herein by reference, contains several examples of suitable materials an emollient. The lotions and creams according to the present invention generally comprise a vehicle system in solution and one or more emollients. The lotions typically comprise from about 1% to about 20%, preferably from about 5% to about 10% emollient; from about 50% to about 90%, preferably from about 60% to about 80% water. A cream typically comprises from about 5% to about 50%, preferably from about 10% to about 20% emollient; and from about 45% to about 85%, preferably from about 50% to about 75% water. The ointments of the present invention may comprise a simple vehicle base of animal or vegetable oils or semi-solid (oleaginous) hydrocarbons; bases for absorption ointments that absorb water to form emulsions; or water soluble carriers, for example, a vehicle in water soluble solution. The ointments may further comprise a thickening agent, such as that described in Sagarin, Cosmetics, Science and Technology, 2nd edition, vol. 1, pp. 72-73 (1972), incorporated herein by reference, and / or an emollient. For example, an ointment can
comprise from about 2% to about 10% of an emollient, and from about 0.1% to about 2% of a thickening agent. The compositions of the present invention useful for personal cleansing ("cleansers") are formulated with a suitable vehicle, for example, as described above, and preferably contain one or more dermatologically acceptable surfactants in an amount that is safe. and effective for personal cleaning. Preferred compositions contain from about 1% to about 90%, most preferably from about 5% to about 10% of a dermatologically acceptable surfactant. The surfactant is suitably selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the art of detergency. Non-limiting examples of possible surfactants include soceteth-20, sodium methylco- coyltaurate, sodium methyloleoyltaurate, sodium lauryl sulfate and betaines such as those described herein. See U.S. Pat. No. 4,800,197 to Kowcz et al, issued January 24, 1989, which is incorporated herein by reference in its entirety, to exemplary surface active agents useful herein. Examples of a wide variety of additional surfactants useful herein are described in McCutcheon's Detergents and Emulsifiers, North American edition (1986), published by Allured Publishing Corporation, which is incorporated herein by reference.
reference in its entirety. Personal cleansing compositions may optionally contain, at their levels established in the art, other materials that are conventionally used in cleaning compositions. The physical form of cleaning compositions is not critical. The compositions can be, for example, formulated as bath rods, liquids, shampoos, bath gels, hair conditioners, hair tonics, pastes or mousses. Bath rods are the most preferred, since they are the most commonly used form of personal cleansing agent to wash the skin. Preferred personal cleansing compositions that are removed by rinsing, such as shampoos, include a suitable delivery system for depositing sufficient levels of active ingredients on the skin and scalp. A preferred delivery system includes the use of insoluble complexes. For a more complete description of said delivery systems, see U.S. Pat. 4,835,148, Barford et al, issued May 30, 1989 and incorporated herein by reference in its entirety. As used herein, the term "base" refers to a liquid, semi-liquid, semi-solid or solid cosmetic for skin that includes, but is not limited to, lotions, creams, gels, pastes, platens and the like. Typically, the base is used over a large area of the skin, such as over the face, to provide a particular appearance. The bases are typically used to provide an adherent base for colored cosmetics such as blush, powders and the like, and tend to hide skin imperfections and to impart
a smooth and uniform appearance to the skin. The bases of the present invention include a dermatologically acceptable vehicle for the essential particulate material and may include conventional ingredients such as oils, dyes, pigments, emollients, fragrances, waxes, stabilizers and the like. Exemplary vehicles and other ingredients that are suitable for use herein are described, for example, in co-pending Patent Application Serial No. 08 / 430,961, filed on April 28, 1995 in the name of Marcia L. Canter, Brain. D. Barford and Brian D. Hofrichter, incorporated herein by reference. The compositions of the present invention are preferably formulated to have a pH of 10.5 or less. The pH values of these compositions preferably range from about 2 to about 10.5, most preferably from about 3 to about 8, even more preferably from about 5 to about 8.
Preferred compositions of this invention Preferred topical compositions of the present invention comprise an emulsion. The emulsions of the present invention may contain one or more of the following:
a) Hydrophobic component The emulsions according to the present invention contain a hydrophobic phase comprising a lipid, oil component,
oily or other hydrophobic component. The compositions of the present invention preferably comprise from about 1% to about 50%, preferably from about 1% to about 30% and most preferably from about 1% to about 10% by weight of the composition of a hydrophobic component. The hydrophobic component can be derived from animals, plants or oil, and can be natural or synthetic (ie, man-made). The hydrophobic components that are preferred are substantially insoluble in water, most preferably essentially insoluble in water. Preferred hydrophobic components are those which have a melting point of about 25 ° C or less under about one atmosphere of pressure, and are suitable for conditioning the skin or hair. Non-limiting examples of suitable hydrophobic components include those selected from the group consisting of: (1) Mineral oil, also known as petrolatum liquid, which is a mixture of liquid hydrocarbons obtained from petroleum. See The Merck Index, tenth edition, index 7048, p. 1033 (1983) and International Cosmetic Ingredient Dictionary, fifth edition, vol. 1, p.415-417 (1993), which are incorporated herein by reference in their entirety. (2) Petrolatum, which is also known as petroleum jelly, is a colloidal system of non-straight chain solid hydrocarbons and high boiling liquid hydrocarbons, in which most of the liquid hydrocarbons are kept within the micelles. See The Merck
Index, tenth edition, section 7047, p. 1033 (1983); Schindler, Drug. Cosmet. Ind., 89. 36-37, 76, 78-80, 82 (1961) and International Cosmetic Ingredient Dictionary, fifth edition, vol. 1, p.537 (1993), which are incorporated herein by reference in their entirety. (3) Straight and branched chain hydrocarbons having from about 7 to about 40 carbon atoms. Non-limiting examples of these hydrocarbon materials include dodecane, isododecane, squalane, cholesterol, hydrogenated polyisobutylene, docosane (i.e., a C22 hydrocarbon), hexadecane, isohexadecane (a commercially available hydrocarbon sold as Permetil® 101 A by Presperse, South Plainfield , NJ). Also useful are C7-C40 isoparaffins which are branched C7-C40 hydrocarbons. (4) C 1 -C 30 alcohol esters of C 1 -C 30 carboxylic acids and C 2 -C 30 dicarboxylic acids, including straight and branched chain materials, as well as aromatic derivatives (such as those used herein with reference to the component hydrophobic, mono- and polycarboxylic acids including straight chain, branched chain and aryl carboxylic acids). Non-limiting examples include diisopropyl sebacate, diisopropyl adipate, isopropyl myristate, isopropyl palmitate, methyl palmitate, myristyl propionate, 2-ethylhexyl palmitate, isodecyl neopentanoate, di-2-ethylhexyl maleate, cetyl palmitate, myristyl myristate, stearyl stearate, isopropyl stearate, methyl stearate, cetyl stearate, behenyl behenate, dioctyl maleate,
dioctyl sebacate, diisopropyl adipate, cetyl octanoate, diisopropyl dilinoleate. (5) Mono-, di-tri-glycerides of C1-C30 carboxylic acids. for example, caprylic / capric triglyceride, caprylic / capric triglyceride of PEG-6, caprylic / capric triglyceride of PEG-8. (6) Alkylene glycol esters of C 1 -C 30 carboxylic acids, for example, ethylene glycol mono- and diesters and propylene glycol mono- and diesters of C 1 -C 30 carboxylic acids, for example, ethylene glycol distearate. (7) Propoxylated and ethoxylated derivatives of the above materials. (8) Mono- and C1-C30 polyesters of sugars and related materials. These esters are derived from a sugar or polyol portion and one or more carboxylic acid moieties. Depending on the acid and constituent sugar, these esters may be in liquid or solid form at room temperature. Examples of liquid esters include: glucose tetraoleate, glucose tetraesters of soybean oil fatty acids (unsaturated), fatty acid maleate tetraesters of mixed soya oil, galactose tetraesters of oleic acid, arabinose tetraesters of linoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate, sucrose pentaoleate, sucrose hexaoleate, sucrose hepatoleate, octaoleate from
sucrose and mixtures thereof. Examples of solid esters include: sorbitan hexaester in which the carboxylic acid ester portions are palmitoleate and arachididate in a 1: 2 molar ratio; the octaester of raffinose in which the carboxylic acid ester portions are linoleate and behenate in a 1: 3 molar ratio; the maltose heptaester wherein the esterifying carboxylic acid moieties are sunflower seed oil and lignocerate fatty acids in a 3: 4 molar ratio; the octaester of sucrose in which the esterifying carboxylic acid moieties are oleate and behenate in a 2: 6 molar ratio; and the sucrose octaester in which the esterifying carboxylic acid moieties are laurate, linoleate and behenate in a 1: 3: 4 molar ratio. A preferred solid material is sucrose polyester in which the degree of esterification is 7-8, and in which the fatty acid moieties are C18 and behenic mono- and / or di-unsaturated, in a molar ratio of unsaturated: behenic from 1: 7 to 3: 5. A solid sugar polyester which is particularly preferred is the sucrose octaester in which there are approximately 7 portions of behenic fatty acid and about a portion of oleic acid in the molecule. Other materials include cottonseed oil or fatty acid esters of sucrose soybean oil. Ester materials are described in more detail in the U.S. Patent. No. 2,831, 854, U.S. Patent. No. 4,005,196 to Jandacek, issued on January 25, 1997; Patent of E.U.A. No. 4,005,195 to Jandacek, issued January 25, 1977, Patent of US. No. 5,306,516 to Letton et al, issued April 26, 1994; Patent
of E.U.A. No. 5,306,515, to Letton et al, issued April 26, 1994; Patent of E.U.A. No. 5,305,514 to Letton et al, issued April 26, 1994; Patent of E.U.A. No. 4,797,300 to Jandacek et al, issued January 10, 1989; Patent of E.U.A. No. 3,963,699 to Rizzi et al, issued June 15, 1976; Patent of E.U.A. No. 4,518,772 to Volpenhein, issued May 21, 1985 and Patent of E.U.A. No. 4,517,360 to Volpenhein, issued May 21, 1985, all of which are hereby incorporated by reference in their entirety. (9) Orqanopolysiloxane oils. The organopolysiloxane oil can be volatile, non-volatile or a mixture of volatile and non-volatile silicones. The term "non-volatile", as used in this context, refers to silicones that are liquid under ambient conditions and have an evaporation point (under a pressure atmosphere) of or greater than about 100 ° C. The term "volatile", as used in this context, refers to all other silicone oils. Suitable organopolysiloxanes can be selected from a wide variety of silicones covering a wide range of volatilities and viscosities. Non-volatile polysiloxanes are preferred. Non-limiting examples of suitable silicones are described in the U.S. Patent. No. 5,069,897 to Orr, issued December 3, 1991, which is hereby incorporated by reference in its entirety. Examples of suitable organopolysiloxane oils include polyalkylsiloxanes, cyclic polyalkylsiloxanes and polyalkylaryl-siloxanes.
Polyalkylsiloxanes useful in the composition herein include polyalkylsiloxanes with viscosities of about 0.5 to about 1,000,000 centistokes at 25 ° C. Said polyalkylsiloxanes can be represented by the general chemical formula R3SiO [R2SiO] xSiR3 wherein R is an alkyl group having from one to about 30 carbon atoms (preferably R is methyl or ethyl, most preferably methyl; mixed in the same molecule), and x is an integer from 0 to about 10,000, selected to achieve the desired molecular weight which can vary up to about 10,000,000. Commercially available polyalkylsiloxanes include polydimethylsiloxanes which are also known as dimethicones, examples of which include the Vicasil® series sold by General Electric Company and the Dow Corning® 200 series sold by Dow Corning Corporation. Specific examples of suitable polydimethylsiloxanes include Dow Corning® 200 fluid having the viscosity of 0.65 centistokes and a boiling point of 100 ° C, Dow Corning® 225 fluid having a viscosity of 10 centistokes and a boiling point of more than 200 °. C and Dow Corning® 200 fluids having viscosities of 50, 350 and 12,500 centistokes, respectively, and boiling points of more than 200 ° C. Suitable dimethicones include those represented by the chemical formula (CH3) 3SiO [(CH3) 2SiO] x [CH3RSiO] and Si (CH3) 3 wherein R is a straight or branched chain alkyl having from two to about 30 atoms of carbon, and (x) and (y) are each one of one to more integers selected to achieve the desired molecular weight
which can vary up to approximately 10,000,000. Examples of these alkyl-substituted dimethicones include cetyldimethicone and lauryldimethicone. Suitable cyclic polyalkylsiloxanes for use in the composition include those represented by the chemical formula [SiR2-O] n wherein R is an alkyl group (preferably R is methyl or ethyl, most preferably methyl) and n is an integer from about 3 to about 8, most preferably n is an integer from about 3 to about 7 and more preferably n is an integer from about 4 to about 6. When R is methyl, these materials are typically known as cyclomethicones. Commercially available cyclomethicones include Dow Corning® 244 fluid having a viscosity of 2.5 centistokes and a boiling point of 172 ° C, which mainly contains the cyclomethicone tetramer (ie n = 4), Dow Corning® 344 fluid having a viscosity of 2.5 centistokes and a boiling point of 178 ° C, containing mainly the pentamer of cyclomethicone (ie n = 5), Dow Corning® 245 fluid having a viscosity of 4.2 centistokes and a boiling point of 205 ° C , which mainly contains a mixture of the tetramer and pentamer of cyclomethicone (ie n = 4 and 5) and Dow Corning® 345 fluid having a viscosity of 4.5 centistokes and a boiling point of 217 ° C, which mainly contains a mixture of tetramer, pentamer and hexamer of cyclomethicone (ie, n = 4, 5 and 6). Also useful are materials such as trimethylsiloxysilicate, which is a polymeric material corresponding to the general chemical formula
(CH2) 3SiO? 2] x [Si? 2ly, where x is an integer from about 1 to about 500 and y is an integer from about 1 to about 500. A commercially available trimethylsiloxysilicate is sold as a mixture with dimethicone as Dow Corning® 593 fluid. The dimethiconols are also suitable for use in the composition. Their compounds can be represented by the chemical formulas R3SiO [R2SiO] xSiR2OH and HOR2SiO [R2SiO] xSiR2? H, where R is an alkyl group (preferably R is methyl or ethyl, most preferably methyl) and x is an integer from 0 to about 500, selected to achieve the desired molecular weight. Commercially available dimethiconols are typically sold as mixtures with dimethicone or cyclomethicone (e.g., Dow Corning® 1401, 1402 and 1403 fluids). The polyalkylaryl siloxanes are also suitable for use in the composition. Polymethylphenylsiloxanes having viscosities of about 15 to about 65 centistokes at 25 ° C are especially useful. It is preferred to use the organopolysiloxanes selected from the group consisting of polyalkylsiloxanes, alkyl-substituted dimethicones, cyclomethicones, trimethylsiloxysilicates, dimethiconols, polyalkylarylsiloxanes and mixtures thereof. It is preferred to use polyalkylsiloxanes and cyclomethicones more herein. Among the polyalkylsiloxanes that are preferred are the dimethicones.
(10) Vegetable oils and hydrogenated vegetable oils. Examples of vegetable oils and hydrogenated vegetable oils include sunflower oil, castor oil, coconut oil, cottonseed oil, shad oil, palm kernel oil, palm oil, peanut oil, soybean oil, rapeseed oil, linseed oil, rice bran oil, pine oil, sesame oil, sunflower seed oil, hydrogenated sunflower seed oil, hydrogenated castor oil, hydrogenated coconut oil, cottonseed oil hydrogenated oil, hydrogenated shad oil, hydrogenated palm kernel oil, hydrogenated palm oil, hydrogenated peanut oil, hydrogenated soybean oil, hydrogenated rapeseed oil, hydrogenated flaxseed oil, hydrogenated rice bran oil, hydrogenated sesame oil , hydrogenated sunflower seed oil and mixtures thereof. (11) Fats and animal oils, for example, lanolin and derivatives thereof, cod liver oil. (12) Alkyl C4-C20 ethers of polypropylene glycols, C1-C20 carboxylic acid esters of polypropylene glycols and dialkyl C8-C30 diethers are also useful. Non-limiting examples of these materials include butyl ether of PPG-14, stearyl ether of PPG-15, dioctyl ether, dodecyl octyl ether and mixtures thereof.
b) Hydrophilic Component The emulsions of the present invention also comprise a hydrophilic component, for example, water or another hydrophilic diluent. The hydrophilic phase can then comprise water, or a combination of water and one or more ingredients soluble or dispersible in water. Hydrophilic components comprising water are preferred.
c) Other components The emulsions and other topical compositions of the present invention may comprise a variety of other ingredients such as those described herein. As will be understood by the person skilled in the art, certain component will be distributed mainly in a hydrophilic phase or a hydrophobic phase, depending on the hydrophilic character of the component in the composition. The emulsions of the present invention preferably include one or more compounds selected from emulsifiers, surfactants, structuring agents and thickeners.
(1) Emulsifiers / surfactants The emulsion may contain an emulsifier / surfactant, generally to help disperse and suspend the discontinuous phase in the continuous phase. A wide variety of said agents can be employed. Emulsifiers / surfactants can be used
known or conventional in the composition, as long as the selected agent is chemically and physically compatible with the essential components of the composition, and provides the desired dispersion characteristics. Suitable agents include emulsifiers / surfactants that do not contain silicone, emulsifiers / silicone surfactants and mixtures thereof. In a preferred embodiment, the composition comprises an emulsifier or hydrophilic surfactant. The compositions of the present invention preferably comprise from about 0.05% to about 5%, most preferably from about 0.05% to about 1% of at least one hydrophilic surfactant. Without intending to be limited by theory, it is believed that the hydrophilic surfactant helps to disperse hydrophobic materials, eg, hydrophobic structuring agents, in the hydrophilic phase. The surfactant, as a minimum, must be sufficiently hydrophilic to disperse in the hydrophilic phase. Preferred surfactants are those having an HLB of at least about 8. The exact surfactant chosen will depend on the pH of the composition and the other components present. Preferred hydrophilic surfactants are selected from nonionic surfactants. Among the nonionic surfactants which are useful herein are those which can be broadly defined as condensation products of long-chain alcohols, for example, C8-30 alcohols, with sugar or starch polymers, i.e.,
glycosides. These compounds can be represented by the formula (S) n-O-R, wherein S is a sugar portion such as glucose, fructose, mannose and galactose; n is an integer from about 1 to about 1000, and R is a C8-30 alkyl group. Examples of long chain alcohols from which the alkyl group can be derived include decyl alcohol, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol and the like. Preferred examples of these surfactants include those in which S is a glucose portion, R is an alkyl group of C8-20 and n is an integer from about 1 to about 9. Commercially available examples of these surfactants include decyl polyglucoside (available as APG 325 CS from Henkel) and lauryl polyglucoside (available as APG 600 CS and 625 CS from Henkel). Other useful nonionic surfactants include the condensation products of alkylene oxides with fatty acids (i.e., alkylene oxide esters of fatty acids). These materials have the general formula RCO (X) nOH, wherein R is an alkyl group of C10-30, X is -OCH2CH2- (ie, derivative of ethylene glycol or oxide) or -OCH2CHCH3- (ie, propylene glycol derivative or oxide) and n is an integer of about 6 to about 200. Other nonionic surfactants are the condensation products of alkylene oxides with two moles of fatty acids (ie, alkylene oxide diesters of fatty acids). These materials have the general formula RCO (X) nOOCR, wherein R is an alkyl group of C10-30, X is -OCH2CH2- (ie, derivative of
ethylene glycol or oxide) or -OCH2CHCH3- (ie, propylene glycol derivative or oxide) and n is an integer from about 6 to about 100. Other nonionic surfactants are the condensation products of alkylene oxides with fatty alcohols (ie to say, alkylene oxide ethers of fatty alcohols). These materials have the general formula R (X) nOR \ wherein R is an alkyl group of C10-30, X is -OCH2CH2- (ie, derivative of ethylene glycol or oxide) or -OCH2CHCH3- (ie, propylene glycol derivative) or oxide) and n is an integer from about 6 to about 100 and R 'is H or a C10-30 alkyl group. Other nonionic surfactants are the condensation products of alkylene oxides with both fatty acids and fatty alcohols [i.e., wherein the polyalkylene oxide moiety is esterified at one end with a fatty acid and etherified (i.e. by means of an ether link) at the other end with a fatty alcohol]. These materials have the general formula RCO (X) nOR \ wherein R and R 'are C10-30 alkyl groups. X is -OCH2CH2 (ie, derived from ethylene glycol or oxide) or -OCH2CHCH3- (propylene glycol derivative or oxide) and n is an integer from about 6 to about 100. Non-limiting examples of these nonionic surfactants derived from alkylene oxide include ceteth-6, ceteth-10, ceteth-12, ceteareth-6, ceteareth-10, ceteareth-12, steareth-6, steareth-10, steareth-12, PEG-6 stearate. PEG-10 stearate, PEG-100 stearate, PEG-12 stearate, PEG-20 glyceryl stearate, PEG-80 glycerylseboate, PEG-10 glyceryl stearate, PEG-30
glycerylcocoate, PEG-80 glycerylcocoate, PEG-200 glycerylseboate, PEG-8 dilaurate, PEG-10 distearate and mixtures thereof. Still other useful nonionic surfactants include the polydihydroxylic acid amide surfactants corresponding to the structural formula:
OR R1 II I R¿- C-N-Z
wherein: R1 is H, C4 alkyl, 2-hydroxyethyl, 2-hydroxypropyl, preferably CrC alkyl, most preferably methyl or ethyl, more preferably methyl; R2 is C5-C31 alkyl or alkenyl, preferably C -C6 alkyl or alkenyl, most preferably Cg-C-? 7 alkyl or alkenyl, more preferably Cn-C? 5 alkyl or alkenyl; and Z is a polyhydroxyhydrocarbyl moiety having a linear hydrocarbyl chain with at least 3 hydroxyls directly connected to the chain, or an alkoxylated derivative (preferably ethoxylated or propoxylated) thereof. Z is preferably a sugar portion selected from the group consisting of glucose, fructose, maltose, lactose, galactose, mannose, xylose and mixtures thereof. An especially preferred surfactant corresponding to the above structure is coconut alkyl-N-methyl glucosamide (ie, wherein the R2CO- portion is derived from coconut oil fatty acids). Methods for making compositions containing polyhydroxy fatty acid amides are described, for example, in the description of
British Patent 809,060 published February 18, 1959, by Thomas Hedley & Co., Ltd; Patent of E.U.A. No. 2,965,576 to E.R. Wilson, issued December 20, 1960; Patent of E.U.A. No. 2,703,798 to A.M. Schwartz, issued March 8, 1955 and Patent of E.U.A. No. 1, 985,424 to Piggott, issued on December 25, 1934; which are incorporated herein by reference in their entirety. Among the preferred nonionic surfactants are those selected from the group consisting of steareth-21, ceteareth-20 ceteareth-12, sucrose cocoate, steareth-100, PEG-100 stearate and mixtures thereof. Other suitable nonionic surfactants for use herein include sugar esters and polyesters, alkoxylated sugar esters and polyesters, C 1 -C 30 fatty acid esters of C 1 -C 30 fatty alcohols, alkoxylated derivatives of fatty acid esters of C 1 -C 30 -C30 of C1-C30 fatty alcohols, alkoxylated ethers of C 1 -C 30 fatty alcohols, polyglyceryl esters of C 1 -C 30 fatty acids, C 1 -C 30 esters of polyols, C 1 -C 30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, acid amides fatty acids, acyl lactylates and mixtures thereof. Non-limiting examples of these emulsifiers that do not contain silicone include: polyethylene glycol monolaure 20 sorbitan (Polysorbate 20), polyethylene glycol 5 soy sterol, Steareth-20, Ceteareth-20, PPG-2 methyl glucose ether distearate, Ceteth-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, Polysorbate 60, glyceryl stearate, trioleate
polyoxyethylene 20 sorbitan (Polysorbate 85), sorbitan monolaurate, sodium stearate polyoxyethylene-4 lauryl ether, polyglyceryl-4 isostearate, hexyl laurate, PPG-2 methyl glucose ether distearate, PEG 100 stearate and mixtures thereof. Another emulsifier useful herein are mixtures of fatty acid esters based on a mixture of sorbitan fatty acid ester or sorbitol and fatty acid ester of sucrose, the fatty acid in each case being preferably C8-C24, very preferably of C10-C20. The preferred fatty acid ester emulsifier is a mixture of C10-C20 fatty acid ester of sorbitan or sorbitol with C10-C16 sucrose fatty acid ester, especially sorbitan stearate and sucrose cocoate. This is commercially available from ICI under the tradename Arlatone 2121. The hydrophilic surfactants useful herein may alternatively or additionally include any variety of cationic, anionic, zwitterionic and amphoteric surfactants, as is known in the art. . See, for example, McCutcheon's, Detergents and Emulsifiers, US edition (1986), published by Allured Publishing Corporation; Patent of E.U.A. No. 5,011, 681 of Ciotti et.al., issued April 30, 1991; Patent of E.U.A. No. 4,421, 769 of Dixon et.al., issued December 20, 1983; and Patent of E.U.A. No. 3,755,560 of Dickert et.al., issued August 28, 1973; These four references are incorporated herein by reference in their entirety.
Exemplary cationic surfactants useful herein include those described in the U.S. Patent. No. 5,151, 209 of McCall et.al., issued September 29, 1992; Patent of E.U.A. No. 5,151, 210 of Steuri et.al., issued September 29, 1992; Patent of E.U.A. No. 5,120,532, of Wells et.al., issued June 9, 1992; Patent of E.U.A. No. 4,387,090, issued by Bolich on June 7, 1983; Patent of E.U.A. 3,155,591, Hilfer, issued November 3, 1964; Patent of E.U.A. No. 3,929,678 to Laughlin et.al., issued December 30, 1975; the patent of E.U.A. No. 3,959,461 to Bailey et.al., issued May 25, 1976, McCutcheon's. Deterqents & Emulsifiers (US edition 1979) M.C. Publishing Co .; and Schwartz, et.al., Surface Active Aqents, Their Chemistry and Tenchnoloqy, New York: Interscience Publishers, 1949; all these documents which are incorporated in the present invention by reference in their entirety. Cationic surfactants useful herein include cationic ammonium salts, such as quaternary ammonium salts, and aminoamides. A wide variety of anionic surfactants are also useful herein. See, for example, U.S. Patent. No. 3,929,678, Laughlin et.al., issued December 30, 1975, which is incorporated herein by reference in its entirety. Non-limiting examples of anionic surfactants include the allyl isethionates (for example, C12-C30), alkyl sulfates and alkyl ether sulfates and salts thereof, alkyl phosphonates and alkyletherphosphonates and salts thereof,
alkylmethyltaurates (for example, C-12-C30). and soaps (for example, alkali metal salts, ie, sodium or potassium salts) of fatty acids. Amphoteric and zwitterionic surfactants are also useful herein. Examples of amphoteric and zwitterionic surfactants that can be used in the compositions of the present invention are those described in detail as derivatives of aliphatic secondary and tertiary amines, in which the aliphatic radical can be straight or branched chain and in where one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably from Cs-C-iß) and one contains an anionic water-soluble group, for example, carboxy, sulfonate, sulfate, phosphate or phosphonate. Examples are alkyliminoacetate and iminodialkanoates and aminoalkanoates, imidazolinium and ammonium derivatives. Other suitable amphoteric and zwitterionic surfactants are those selected from the group consisting of betaines, sultaines, hydroxysultaines, alkyl sarcosinates (eg C-12-C30), and alkanoyl sarcosinates. Preferred emulsions of the present invention include an emulsifier or surfactant that contains silicone. A wide variety of silicone emulsifiers are useful herein. These silicone emulsifiers are almost always organopolysiloxane organopolysiloxanes, also known to those skilled in the art as silicone surfactants. Useful silicone emulsifiers include dimethicone copolyols. These materials are polydimethylsiloxanes that have been
modified to include polyether side chains, such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains and polyether chains containing portions derived from ethylene oxide and propylene oxide. Other examples include alkyl-modified dimethicone copolyols, ie, compounds containing pendant C2-C30 side chains. Even other useful dimethicone copolyols include materials having various cationic, anionic, amphoteric and zwitterionic pendant moieties. The emulsifiers of dimethicone copolyols useful herein can be described by the following general structure:
wherein R is straight, branched or cyclic alkyl of C1-C30 and R2 is selected from the group consisting of ~ (CH2) n ~ O- (CH2CHR3O) m-H,
- (CH2) n -O- (CH2CHR3O) m- (CH2CHR4O) or -H, wherein n is an integer from 3 to about 10; R3 and R4 are selected from the group consisting of H and straight or branched chain alkyl of C1-C6, such that R3 and R4 are not the same simultaneously; and m,
or, x, yy are selected such that the molecule has an overall molecular weight of about 200 to about 10,000,000, with m, o, x, yy being independently selected from zero or greater integers, such that myo they are not zero simultaneously and z is selected independently of integers of 1 or greater. It is recognized that positional isomers of these copolyols can be achieved. The chemical representations illustrated above for the portions of R2 containing the groups R3 and R4 are not intended to be limiting, but are illustrated as such for convenience. Also useful herein are, although they are not strictly classified as dimethicone copolyols, the silicone surfactants as illustrated in the structures of the preceding paragraph, wherein R2 is
~ (CH2) n-0-R5, wherein R5 is a cationic, anionic, amphoteric or zwitterionic moiety. Non-limiting examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers herein include copolymers of polydimethylsiloxane-polyether with pendant polyethylene oxide side chains, polydimethylsiloxane-polyether copolymers with pendant polypropylene oxide side chains, copolymers of polydimethylsiloxane-polyether with side chains of mixed propylene oxide and polyethylene oxide pendants, copolymers of polydimethylsiloxane-polyether with side chains of mixed poly (ethylene) (propylene) pendants, copolymers of polydimethylsiloxane-polyether with side chains
organobetaine pendants, polydimethylsiloxane-polyether copolymers with pendant carboxylate side chains, polydimethylsiloxane-polyether copolymers with pendent quaternary ammonium side chains; and in addition other modifications of the foregoing copolymers containing pendent straight, branched or cyclic C2-C30 alkyl portions. Examples of commercially available dimethicone copolyols, useful herein, sold by Dow Corning Corporation are Dow Corning® 190,193, Q2-5220, 2501 Wax, 2-5324 Fluid, and 3225C (the latter material being sold as a mixture with cyclomethicone). Copolyol of cetyldimethicone is commercially available as a mixture with polyglyceryl isostearate-4 (y) hexyl laurate and sold under the trademark ABIL® WE-09 (available from Goldschmidt). Copolyol of cetyldimethicone is also commercially available as a mixture with hexyl laurate (and) polyglyceryl-3 (y) cetyldimethicone oleate and is sold under the tradename ABIL® WS-08 (also available from Goldschmidt). Other non-limiting examples of dimethicone copolyols also include lauryl dimethicone copolyol, dimethicone copolyol acetate, dimethicone copolyol adipate, dimethicone copolyol amine, dimethicone copolyol behenate, dimethicone copolyol butyl ether, dimethicone copolyol hydroxystearate, isostearate of dimethicone copolyol, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyol phosphate, and dimethicone copolyol stearate. See International
Cosmetic Inqredient Dictionary. fifth edition, 1993, which is incorporated by reference herein in its entirety. The dimethicone copolyol emulsifiers useful herein are described, for example, in U.S. Pat. No. 4,960,764 to Figueroa, Jr. et.al., issued October 2, 1990; European Patent No. EP 330,369, by SaNogueira, published on August 30, 1989; G. H. Dahms, et.al. "New Formulation Possibilities Offered by Silicone Copolyols," Cosmetics & Toiletries, vol. 110, pp. 91-100, March 1995; M. E. Carlotti et al., "Optimization of W / O-S Emulsions and Study of the Quantitative Relatonships Between Ester Structure and Emulsion Properties," J. Dispersion Science And Technology, 13 (3), 315-336 (1992); P. Hameyer, "Comparative Technological Investigations of Organic and Organosilicone Emulsifiers in Cosmetic Water-in-Oil Emulsion Preparations /? APPI 28 (4), pp. 88-128 (1991); J. Smid-Korbar et.al.," Efficiency and usability of silicone surfactants in emulsions. "Provisional Communication, International Journal of Cosmetic Science, 12, 135-139 (1990); and DG Krzysik et.al.," A New Silicone Emulsifier for Water-in-Oil Systems, " Druq and Cosmetic Industrv, vol 146 (4) pp. 28-81 (April 1990), incorporated herein by reference in its entirety.
(2) Structuring Agent The compositions herein, and especially the emulsions herein, may contain a structuring agent. Structuring agents are particularly preferred in oil-in-water emulsions
of the present invention. Without being limited to theory, it is believed that the structuring agent helps to provide rheological characteristics to the composition that contribute to the stability of the composition. For example, the structuring agent tends to assist in the formation of liquid crystal gel network structures. The structuring agent can also function as an emulsifier or surfactant. Preferred compositions of this invention comprise from about 1% to about 20%, most preferably from about 1% to about 10%, most preferably still from about 2% to about 9% of one or more structuring agents. Preferred structuring agents are those having an HLB of about 1 to about 8 and having a melting point of at least about 45 ° C. Suitable structuring agents are those selected from the group consisting of saturated C to C 30 fatty alcohols, saturated C 16 to C 30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, diols of C- 6 to C3O saturated, saturated C-? 6 to C30 monoglycerol ethers, saturated C-iß to C30 hydroxy fatty acids, hydroxylated and non-hydroxylated saturated fatty acids from C to C3o > saturated ethoxylated fatty acids of C14 to C30, amines and alcohols containing from about 1 to about 5 moles of ethylene oxide diols, saturated glyceryl monoethers of Cu to C30 with a monoglyceride content of at least 40%, ethers of polyglycerol saturated from C to C30
having from about 1 to about 3 alkyl groups and from about 2 to about 3 units of saturated glycerol, glyceryl monoethers of C to C30. sorbitan mono / diesters of C1 to C30, saturated ethoxylated mono / diesters of Cu to C30 with about 1 to about 5 moles of ethylene oxide, saturated methylglucoside esters of Cu to C30, saturated mono / diesters of sucrose of Cu to C30, saturated ethoxylated methylglucoside esters of Cu to C30 with about 1 to about 5 moles of ethylene oxide, saturated polyglycosides of C to C30 having an average of between 1 to 2 glucose units and mixtures thereof, which have a melting point of at least about 45 ° C. The preferred structuring agents of the present invention are selected from the group consisting of stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof. The most preferred structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2 ), the polyethylene glycol ether of cetyl alcohol that has
an average of about 2 ethylene oxide units, and mixtures thereof. Even more preferred structuring agents are selected from the group consisting of stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth-2, and mixtures thereof.
(3) Thickening agent (including chelating agents and thickeners) The compositions of the present invention may also include a thickening agent, preferably from about 0.1% to about 5%, most preferably from about 0.1% to about 3%, and very preferably still about 0.25% at about
2%, of a thickening agent. The non-limiting classes of thickening agents include those selected from the group consisting of: (i) Carboxylic acid polymers These polymers are crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids and salts and esters of these acrylic acids and substituted acrylic acids, wherein the entanglement agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol. Preferred carboxylic acid polymers are of two general types. The first type of polymer is an entangled homopolymer of an acrylic acid monomer or derivative of the
same (for example, wherein the acrylic acid has substituents at the two and three carbon positions independently selected from the group consisting of C? _4 alkyl, -CN, -COOH, and mixtures thereof). The second type of polymer is an entangled copolymer having a first monomer selected from the group consisting of an acrylic acid monomer or derivative thereof (as described in the previous sentence), an acrylate ester monomer of short chain alcohol (i.e., a C1.4) or derivative thereof (eg, wherein the acrylic acid portion of the ester has substituents at the two and three carbon positions independently selected from the group consisting of alkyl of C1-4 -CN, -COOH, and mixtures thereof), and mixtures thereof; and a second monomer which is a long-chain (ie C8-C4o) alcohol acrylate ester monomer or derivative thereof (eg, wherein the acrylic acid portion of the ester has substituents at the two carbon positions). and three independently selected from the group consisting of C- | 4 alkyl, -CN, -COOH, and mixtures thereof). The combinations of these two types of polymers are also useful herein. In the first type of entangled homopolymers, the monomers are preferably selected from the group consisting of acrylic acid, methacrylic acid, methacrylic acid, and mixtures thereof, with acrylic acid being most preferred. In the second type of entangled copolymers, the acrylic acid monomer or derivative thereof is
preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid and mixtures thereof, with acrylic acid, methacrylic acid and mixtures thereof being most preferred. The short chain alcohol acrylate ester monomer or derivative thereof is preferably selected from the group consisting of alcohol acrylate esters of C-1.4, alcohol methacrylate esters of C1.4, ethacrylate esters of C1-4 alcohol and mixtures thereof, with the most preferred being C1-4 alcohol acrylate esters, C1.4 alcohol methacrylate esters and mixtures thereof. The long chain alcohol acrylate ester monomer is selected from the alkyl acrylate esters of Cs-4o, with the alkyl acrylate esters of C-? Or -30 being preferred. The crosslinking agent in both types of polymers is a polyalkenyl polyether of a polyhydric alcohol containing more than one alkenyl ether group per molecule, wherein the parent polyhydric alcohol contains at least 3 cn atoms and at least three hydroxyl groups. Preferred entanglements are those selected from the group consisting of allylic ethers of sucrose and allylic ethers of pentaerythritol, and mixtures thereof. These polymers useful in the present invention are described in greater detail in the U.S. Patent. No. 5,087,445, Haffey et. al., issued on February 11, 1992; Patent of E.U.A. No. 4,509,949 to Huang et. al., issued on April 5, 1985; Patent of E.U.A. No. 2,798,053, Brown, issued July 2, 1957; that are incorporated by
reference in the present in its entirety. See also, CTFA International Cosmetic Ingredient Dictionary, 4th edition 1991, p. 12 and 80; which are also incorporated herein by reference in their entirety. Examples of commercially available homopolymers of the first type useful herein include carbomers, which are homopolymers of acrylic acid entangled with allylic ethers of sucrose or pentaerythritol. Carbomers are available as the Carbopol® 900 series from B.F. Goodrich (for example, Carbopol® 954). Examples of commercially available copolymers of the second type useful herein include copolymers of C10-30 alkyl acrylates with one or more acrylic acid monomers, methacrylic acid or one of their short chain esters (ie, C-1-4), wherein the entanglement agent is an allyl ether of sucrose or pentaerythritol. These copolymers are known as cross-linked alkyl acrylate polymers of C-? O-30 / acrylates and are commercially available as Carbopol® 1342, Carbopol® 1382Pemulen TR-1, and Pemulen TR-2, from B.F. Goodrich. In other words, examples of carboxylic acid polymer thickeners useful herein are those selected from the group consisting of carbomers, C polí-30 acrylate alkyl acrylate cross-linked polymers, and mixtures thereof. ii) Interlaced polyacrylate polymers The crosslinked polyacrylate polymers useful as thickeners or gelling agents include cationic and nonionic polymers, cationics being generally preferred. Examples of non-ionic polyacrylate polymers intertwined
Useful and interlaced cationic polyacrylate polymers are those described in the U.S. Patent. 5,100,660, Hawe et. al., issued on March 31, 1992; Patent of E.U.A. 4,849,484, by Heard, issued July 18, 1989; Patent of E.U.A. 4,835,206, Farrar et al. al., issued May 30, 1989; Patent of E.U.A. 4,628,078 to Glober et. al., issued on December 9, 1986; Patent of E.U.A. 4,599,379, by Flesher et. al., issued July 8, 1986; and EP 228,868, Farrar et al. al., published July 15, 1987; all incorporated herein by reference in their entirety. The crosslinked polyacrylate polymers are high molecular weight materials which can be characterized by the general formula: (A)? (B) m (C) n and comprises the monomer units (A) ?, (B) m. and (C) n, wherein (A) is a dialkylaminoalkyl acrylate monomer or its acid addition salt or quaternary ammonium salt, (B) is a dialkylaminoalkyl methacrylate monomer or its acid addition salt or ammonium salt quaternary, (C) is a monomer that can be polymerized with (A) or (B), for example a monomer having a carbon-carbon double bond or other functional group that can be polymerized, I is an integer of 0 or greater, m is an integer of 0 or greater, n is an integer of 0 or greater, but where I or m, or both, must be 1 or greater. The monomer (C) can be selected from any of the monomers commonly used. Non-limiting examples of these monomers include ethylene, propylene, butylene, isobutylene, eicosene, maleic anhydride, acrylamide, methacrylamide, maleic acid, acrolein,
cyclohexene, ethyl vinyl ether and methylvinyl ether. The alkyl portions of the monomers (A) and (B) are short chain length alkyls, such as C-i-Cβ, preferably C 1 -C 5, most preferably C 1 -C 3, and most preferably still C C 2. When quaternized, the polymers are preferably quatemized with short chain alkyls, ie, C Cs, preferably C 1 -C 5, most preferably C 1 -C 3, and most preferably still C 2 -C 2. Acid addition salts refer to polymers having protonated amino groups. The acid addition salts can be prepared through the use of halogens (for example chloride), acetic, phosphoric, nitric, citric and other acids. These polymers (A)? (B) m (C) n also comprise an interlacing agent, which is almost always a material that contains two or more unsaturated functional groups. The entanglement agent is reacted with the monomer units of the polymer and is incorporated into the polymer, whereby it forms covalent bonds or bonds between two or more individual polymer chains or between two or more sections of the same polymer chain. Non-limiting examples of suitable entanglement agents include those selected from the group consisting of methylenebisacrylamides, diallyldiallylalkylammonium halides, polyalkenyl polyethers of polyhydric alcohols, allyl acrylates, vinyloxyalkylacrylates, and polyfunctional vinylidenes. Specific examples of entanglement agents useful herein include those selected from the group consisting of methylenebisacrylamide, ethylene glycol di- (meth) acrylate,
di- (meth) acrylamide, cyanomethylacrylate, vinyloxyethylacrylate, vinyloxyethyl methacrylate, allyl pentaerythritol, diallyl ether of trimethylolpropane, sucrose of allyl, butadiene, isoprene, divinylbenzene, divinylnaphthalene, ethyl vinyl ether, methyl vinyl ether and allyl acrylate. Other entanglements include formaldehyde and glyoxal. Methylene bisacrylamide is used herein as an entanglement agent. The amounts of wide variation of the entangling agent can be employed depending on the desired properties in the final polymer, for example, viscosifying effect. Without being limited to the theory, it is believed that the incorporation of an entanglement agent in these cationic polymers provides a material that is a more effective viscosifying agent without negative effects, such as corriosity and viscosity degradation in the presence of electrolytes. The entanglement agent, when present, may include from about 1 ppm to about 1000 ppm, preferably from about 5 ppm to about 750 ppm, most preferably from about 25 ppm to about 500 ppm, most preferably still from about 100 ppm. ppm to about 500 ppm, and even more preferably from about 250 ppm to about 500 ppm of the total weight of the polymer on a weight / weight basis. The intrinsic viscosity of the entangled polymer, measured in a one molar sodium chloride solution at 25 ° C, is generally above 6, preferably from about 8 to about 14. The molecular weight (weight average) of the entangled polymers of the present is
high and it is believed that it is almost always between about 1 million and about 30 million. The specific molecular weight is not critical, and average molecular weights of greater or lesser weight may be employed, as long as the polymer retains the intended viscosity effects. Preferably, a 1.0% solution of the polymer (on an active base) in deionized water will have a viscosity at 25 ° C of at least about 20,000 cP, preferably at least about 30,000 cP, when measured at 20 RPM by an RVT of Brookfield (Brookfield Engineering Laboratories, Inc. Stoughton, MA, USA). These cationic polymers can be made by polymerizing an aqueous solution containing from about 20% to about 60%, generally from about 25% to about 40%, by weight of monomer, in the presence of an initiator (hence common oxide-reduction or thermal) until the polymerization is complete. The entanglement agent can also be added to the solution of the monomers to be polymerized, for incorporation into the polymer. In polymerization reactions, in general, the temperature starts between about 0 ° C and 95 ° C. The polymerization can be conducted by forming a reverse phase dispersion of an aqueous phase of the monomers (and also any additional entanglement agents) in a non-aqueous liquid, for example mineral oil, lanolin, isododecane, oleyl alcohol, and others. volatile and non-volatile esters, ethers, and alcohols and the like.
All percentages describing the polymer in this section of the description herein are molars, unless otherwise specified. When the polymer contains monomer (C), the molar ratio of monomer (C), based on the total molar amount of (A), (B) and (C), can be from 0% to about 99%. The proportions of (A) and (B) can each be from 0% to 100%. When the acrylamide is used as the monomer (C), it will preferably be used at a level of about 20% to about 99%, most preferably from about 50% to about 90%. Where both monomers (A) and (B) are present, the ratio of monomer (A) to monomer (B) in the final polymer on a molar basis, is preferably from 99: 5 to about 15:85, most preferably from around 80:20 to about 20:80. Alternatively, in another class of polymers, the ratio is from about 5:95 to about 50:50, preferably from about 5:95 to about 25:75. In another alternative class of polymers the ratio (A) :( B) is around 50:50 to about 85:15. Preferably the ratio (A) :( B) is from about 60:40 to about 85:15, most preferably from 75:25 to about 85:15. Most preferable is when the monomer (A) is not present and the ratio of the monomer (B): monomer (C) is from about 30:70 to about 70:30, preferably from about 40:60 to
about 60:40 and most preferably about 45:55 to about 55:45. The cationic polymers which are useful herein and which are especially preferred are those corresponding to the general structure (A)? (B) m (C) n where I is zero, (B) is methyl quaternized dimethylaminoethyl methacrylate , the ratio of (B) :( C) is from about 45:55 to about 55:45, and the entanglement agent is methylenebisacrylamide. An example of such a cationic polymer is one that is commercially available as a mineral oil dispersion (which may also include various dispersing aids such as PPG-1 trideceth-6) under the trade name Saleare® SC92 from Allied Colloids Ltd. (Norfolk , Virginia). This polymer has the proposed designation CTFA, "Polyquaternium 32 (and) mineral oil". Other cationic polymers useful herein are those that do not contain acrylamide or other monomers (C), ie, n is zero. In these polymers the monomer components (A) and (B) are as defined above. An especially preferred group of these polymers that do not contain acrylamide is one where I is also zero. In this case, the polymer is basically a homopolymer of a dialkylammonoalkyl methacrylate monomer or its acid addition salt or quaternary ammonium salt. These dialkylaminoalkyl methacrylate polymers preferably contain an entanglement agent as described above.
A cationic polymer, which is essentially a homopolymer, useful herein is a corresponding to the general structure (A)? (B) m (C) n where I is zero, (B) is quaternized dimethylaminoethyl methacrylate of methyl, n is zero and the entanglement agent is methylenebisacrylamide. An example of said homopolymer is commercially available as a mixture containing about 50% of the polymer, about 44% mineral oil, and about 6% of PPG-1 trideceth-6 as a dispersing auxiliary, from Allied Colloids Ltd, (Norfolk , VA) under the trade name Saleare® SC95. This polymer has recently been given the designation CTFA "Polyquaternium 37 (and) mineral oil (and) PPG-1 Trideceth-6". (iii) Polyacrylamide Polymers Also useful herein are polyacrylamide polymers, especially non-ionic polyacrylamide polymers including branched or unbranched substituted polymers. These polymers can be formed of a wide variety of monomers including acrylamide and methacrylamide which are substituted or unsubstituted with one or two alkyl groups (preferably C-i to C5). Preferred are acrylate amide and methacrylate amide monomers in which the amide nitrogen is substituted, or unsubstituted with one or two Ci to C5 alkyl groups (preferably methyl, ethyl or propyl), for example, acrylamide, methacrylamide, N-methacrylamide , N-methylmethacrylamide, N, N-dimethylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide, and N, N-dimethylacrylamide. These polymers have a higher molecular weight than
1, 000,000 preferably greater than about 1, 5,000,000 and go up to about 30,000,000. Among these polyacrylamide polymers especially preferred is the nonionic polymer having the CTFA designation of polyacrylamide and isoparaffin and laureth-7, available under the tradename Sepigel 305 from Seppic Corporation (Fairfield, NJ). Other polyacrylamide polymers useful herein include multiple block copolymers of acrylamides and acrylamides substituted with acrylic acids and substituted acrylic acids. Commercially available examples of these multi-block copolymers include Hypan SR150H, SS500V, SS500W, SSSA100H, from Lipo Chemicals, Inc., (Patterson, NJ). (iv) Polysaccharides A wide variety of polysaccharides is useful herein. By "polysaccharides" refers to gelling agents that contain a base structure of repeating sugar units (i.e., carbohydrates). Non-limiting examples of polysaccharide gelling agents include those selected from the group consisting of cellulose, carboxymethylhydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylhydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof. thereof. Also useful herein are celluloses substituted with alkyl. In these polymers, the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxyethylated or hydroxypropyl) to form a hydroxyalkylated cellulose which
then it is modified with a straight or branched chain alkyl group of C 10 -C 30 through a linkage with ether. Almost always, these polymers are ethers of straight or branched C10-C30 chain alcohols with hydroxyalkyl-fluosols. Examples of alkyl groups useful herein include those selected from the group consisting of stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, cocoyl (i.e. alkyl groups derived from coconut oil alcohols), palmityl, oleyl, linoleyl, linolenyl , ricinoleyl, behenyl, and mixtures thereof. Among the alkyl hydroxyalkyl cellulose ethers is the material which has received the CTFA designation of cetylhydroxyethylcellulose, which is the ether of cetyl alcohol and hydroxyethylcellulose. This material is sold under the trade name Natrosol® CS Plus by Aqualon Corporation. Other useful polysaccharides include scleroglucans comprising a straight chain of (1-> 3) glucose-linking units with one (1-> 6) glucose linked every three units, a commercially available example being Clearogel ™ CS11 by Michel Mercier Prodcts Inc. (Mountainside, NJ). (v) Gums Other additional gelling agents and thickeners herein include materials that are derived primarily from natural sources. Non-limiting examples of these gelling agent gums include materials selected from the group consisting of acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gum gelano,
guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silica, hydroxypropylchitosan, hydroxypropylguar, karaya gum, seaweed, locust bean gum, natural gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyldextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof. (vi) Vinyl ether / maleic anhydride crosslinkers Other additional thickeners and gelling agents useful herein include crosslinked copolymers of alkylvinyl ethers and maleic anhydride. In these copolymers, the vinyl ethers are represented by the formula R-O-CH == CH2 wherein R is a C1-C6 alkyl group, preferably R is methyl. The preferred entanglement agents are C4-C20 dienes, preferably C6 to C16 dienes, and most preferably C8 to C12 dienes. A particularly preferred copolymer is that which is formed of methyl vinyl ether and maleic anhydride, wherein the copolymer has been entangled with decadiene, and wherein the polymer, when diluted as a 0.5% aqueous solution at a pH of 7 and 25 ° C, have a viscosity of 50,000-70,000 cps when measured using a Brookfield RTV viscometer, spindle # 7 at 10 rpm. This copolymer has the CTN / MA decadiene crossed polymer of CTFA designation and is commercially available as Stabileze ™ 06 from International Specialty Products (Wayne NJ).
(vii) Interlaced Poly (N-vinylpyrrolidones) The interlaced polyvinyl (N-pyrrolidones) useful herein as further thickeners and gelling agents include those described in the U.S. Pat. No. 5,139,770, to Shih et al, published August 18, 1992, and the U.S. Patent. No. 5,073,614, to Shih et al, published December 17, 1991, both Patents are hereby incorporated by reference in their entirety. Almost always, these gelling agents contain from about 0.25% to about 1% by weight of an entanglement agent selected from the group consisting of divinyl ethers and diallyl ethers of terminal diols containing from about 2 to about 12 carbon atoms, divinyl ethers and diallyl ethers of polyethylene glycols containing from about 2 to about 600 units, dienes having from about 6 to about 20 carbon atoms, divinylbenzene, vinyl and allylic ethers of pentaerythritol, and the like. Typically, these gelling agents have a viscosity of about 25,000 cps at about 40,000 cps when measured as a 5% aqueous solution at 25 ° C using a Brookfiels RVT viscometer with spindle # 6 at 10 rpm. Commercially available examples of these polymers include ACP-1120, ACP-1179, and ACP-1180, available from International Specialty Products (Wayne, NJ). Thickening agents that are suitable for use herein also include those described in the U.S. Patent. No. 4,387,107 to Klein et.al., published June 7, 1983 and "Encyclopedia of
Polymer and Thickeners for Cosmetics, "RY Lochhead and WR Fron, eds., Cosmetics &Toiletries, Vol 108. pp. 95-135 (May 1993), which is incorporated herein by reference in its entirety. Preferred of the present invention include a thickening agent selected from the group consisting of carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof, most preferably selected from the group consisting of crosslinked polyacrylate polymers, polyacrylamide polymers , and mixtures thereof.
Optional Components The topical compositions of the present invention may comprise a wide variety of optional components, so long as said optional components are physically and chemically compatible with the essential components described herein, and do not affect the stability, efficacy or other benefits of use. associated with the compositions of the present invention. The optional components may be dispersed, dissolved or the like in the vehicle of the present compositions. The optional components include aesthetic agents and active agents. For example, the compositions may include, in addition to the essential components of the composition, absorbers (including oil absorbers such as clay and polymeric absorbents),
abrasives, anti-staling agents, anti-foaming agent, antimicrobial agents (for example a compound capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes and are useful, for example, for controlling acne and / or avoiding topical composition ), binders, biological additives, pH regulating agents, density agents, chemical additives, cosmetic biocides, denaturants, cosmetic astringents, medicinal astringents, external analgesics, film formers, humectants, opacifying agents, fragrances, perfumes, pigments, dyes, essential oils, skin sensitizers, emollients, skin-softening agents, skin-healing agents, pH adjusters, plasticizers, preservatives, preservative improvers, propellants, reducing agents, skin conditioning agents, agents for increasing skin penetration in the skin, skin protectors, solvents, agents of suspension, emulsifiers, thickening agents, solubilizing agents, polymers to assist the film-forming properties and substantivity of the composition (such as a copolymer of eicosene and vinylpyrrolidone, an example available from GAF Chemical Corporation as Ganez® V-220) , waxes, sunscreens, sunscreens, ultraviolet light absorbers or dispersing agents, artificial tanning agents, antioxidants and / or radical scavengers, chelating agents, sequestrants, anti-acne agents, anti-inflammatory agents, anti-androgens, depilation agents, agents of peeling / exfoliants, organic hydroxy acids, vitamins and derivatives of
the same (including dispersing and water-soluble vitamins such as vitamin C and ascorbyl phosphates), compounds that stimulate the production of collagen and natural extracts. Other materials are known in the art. Non-exclusive examples of such materials are described in Harry's Cosmeticoloqy, 7th Ed., Harry & Wiikinson (Hill Publishers, London 1982); in Pharmaceutical Dosaqe Forms-Disperse Systems; Lieberman, Rieger & Banker, Vols. 1 (1988) & 2 (1989); Marcel Decker, Inc .; in The Chemistry and Manufacture of Cosmetics, 2nd Ed., by Navarre (Van Nostrand 1962-1965); and in The Handbook of Cosmetic Science and Technology, 1st Ed. Knowlton & Pearce (Elsevier 1993) and these can also be used in the present invention. In a preferred embodiment the composition also includes an active useful for chronically regulating the condition of the skin. Said materials are those that show benefits in the appearance of the skin followed by the chronic application of the composition containing said materials. Materials that have this effect include, but are not limited to, vitamin B3 compounds and retinoids. Specific examples of optional components include the following.
A) Vitamin B3 Compounds In a preferred embodiment, the compositions of the present invention comprise a safe and effective amount of a compound of
vitamin B3. The vitamin B3 compound improves the skin appearance benefits of the present invention, especially by regulating the condition of the skin including regulatory signs of skin aging, very specifically wrinkles, lines and pores. The compositions of the present invention preferably comprise from about 0.01% to about 50%, most preferably from about 0.1% to about 10%, still most preferably from about 0.5% to about 10%, and even more preferably from about 1% to about 5%, preferably from about 2% to about 5%, of the vitamin B3 compound. As used herein "the vitamin B3 compound" refers to a compound having the formula:
wherein R is -CONH2 (ie, niacinamide), -COOH (ie, nicotinic acid) or -CH2OH (nicotinyl alcohol); derivatives thereof; and you come out of any of the following. Examples of derivatives of the vitamin B3 compounds include nicotinic acid esters including non-vasodilating esters of nicotinic acid, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
Suitable esters of nicotinic acid include nicotinic acid esters of CrC22 alcohols, preferably CIC-IT, most preferably of C Cß- The alcohols are preferably straight or branched chain, cyclic or acyclic, saturated or unsaturated (including aromatic), or substituted or not replaced. The esters are preferably non-vasodilators. As used herein, "non-vasodilator" means that the ester does not commonly produce an immediate visible response after application to the skin of the compositions in question (the majority of the general population does not experience a visible immediate response, although said compounds may cause vasodilatation not visible to the eye, ie, the ester is not rubifacient). Non-vasodilating nicotinic acid esters include tocopherol nicotinate and inositol hexanicotinate; the tocopherol nicotinate is preferred. Other derivatives of the vitamin B3 compound are the niacinamide derivatives which are the result of the substitution of one or more of the hydrogens of the amide group. Non-limiting examples derived from niacinamide useful herein include nicotinylamino acids derived, for example, from the reaction of an activated nicotinic acid compound (e.g., nicotinic acid azide or nicotinyl chloride) with an amino acid, and nicotinyl alcohol esters of organic carboxylic acids (for example C1-C18). Specific examples of such derivatives include nicotinuric acid (C8H8N2O3) and nicotinylhydroxamic acid (C6H6N2O2), which have the following chemical structures:
Nicotinuric acid:
Nicotinylhydroxamic acid:
Some examples of nicotinyl alcohol esters include nicotinyl alcohol esters of carboxylic acids, salicylic acid, acetic acid, glycolic acid, palmitic acid and the like. Other non-limiting examples of vitamin B3 compounds useful herein are 2-chloronicotinamide, 6-aminonicotinamide, 6-methylnicotinamide, n-methyl-nicotinamide, n-n-diethylnicotinamide, n- (hydroxymethyl) -nicotinamide, quinolinic acid,! mida, nicotinanilide, n-benzylnicotinamide, n-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methylisonicotinic acid, thionicotinamide, nialamide, 1- (3-pyridylmethyl) urea, 2-mercaptonicotinic acid, nicomol, and niaprazine.
Examples of the above vitamin B3 compounds are well known in the art and are commercially available from a large number of sources, for example Sigma Chemical Company (St. Louis,MO); ICN Biomedicals, Inc. (Irvin, CA) and Aldrich Chemical Company (Milwaukee, Wl). One or more vitamin B3 compounds can be used herein. The preferred vitamin B3 compounds are niacinamide and tocopherol nicotinate. Niacinamide is preferred. When used, salts, derivatives, and derivatives of niacinamide salts are preferably those that have substantially the same efficacy as niacinamide in the methods for regulating the skin condition described herein. The salts of the vitamin B3 compound are also useful herein. Non-limiting examples of salts of vitamin B3 compound herein include organic or inorganic salts such as inorganic salts with anionic inorganic species (eg, chloride, bromide, iodide, carbonate, preferably chloride), and organic salts of carboxylic acid (including mono, di and tri C 1 -C 18 carboxylic acid salts, for example, acetate, salicylate, glycolate, lactate, malate, citrate, preferably monocarboxylic acid salts such as acetate). These and other salts of the vitamin B3 compound can be readily prepared by those skilled in the art, for example, as described by W. Wenner, "The Reaction of L-Ascorbic and D-losascorbic Acid with Nicotinic Acid and Its Amide", J. Organic
Chemistry, VOL. 14, 22-26 (1949), which is incorporated herein by reference. Wenner describes the synthesis of the ascorbic acid salt of niacinamide. In a preferred embodiment, the nitrogen ring of the vitamin B3 compound is substantially chemically free (eg, unbound and / or unimpeded), or after supplying the skin is substantially chemically free (from "chemically free" alternative way from hereinafter may be referred to as "not complex". Most preferably, the vitamin B3 compound essentially does not form complex. Therefore, if the composition contains vitamin B3 compound in a salt form or other form that forms complex, said complex is preferably substantially reversibly, most preferably substantially reversibly, after delivering the composition to the skin. For example, said complex should be substantially reversible at a pH of about 5.0 to about 6.0. Said reversibility can be easily determined by one skilled in the art. Most preferably, the vitamin B3 compound is substantially not complex in the composition prior to delivery to the skin. Some approaches to minimize or avoid the formation of undesirable complexes include the omission of materials that form substantially irreversible complexes or other complexes with the vitamin B3 compound, pH adjustment, adjustment of ionic resistance, the use of agents
surfactants and formulation where the vitamin B3 compound and materials that form complexes are in different phases. Such approaches are well known within the level of those skilled in the art. Thus, in a preferred embodiment, the vitamin B3 compound contains a limited amount of the salt form and is preferably substantially free of salts of a vitamin B3 compound. Preferably the vitamin B3 compound contains less than about 50% of said salt, and is preferably substantially free of the salt form. The vitamin B3 compound in the compositions thereof having a pH of from about 4 to about 7, almost always contains less than about 50% of the salt form. The vitamin B3 compound may be included as the substantially pure material, or an extract obtained by suitable chemical and / or physical isolation from natural sources (e.g., plants). Preferably, the vitamin B3 compound is substantially pure, more preferably, essentially pure.
B) Anti-inflammatory agents A safe and effective amount of an anti-inflammatory agent may be added to the compositions of the present invention, preferably from about 0.1% to about 10%, more preferably from
about 0.5% to about 5% of the composition. The anti-inflammatory agent improves the appearance benefits of the skin of the present invention, for example, said agents contribute to a more uniform and acceptable skin tone or color. The exact amount of anti-inflammatory agent that will be used in the compositions will depend on the specific anti-inflammatory agent employed, since said agents vary widely in potency. Steroidal antiinflammatory agents include, but are not limited to, corticosteroids, such as hydrocortisone, hydroxyltriamcinolone, alpha-methyldexametasone, dexamethasone phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, deoxymethasone, deoxycorticosterone acetate, dexamethasone, dichlorisone, diacetate, diflorasone, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumetasone pivalate, fluosinolone acetonide, fluocinonide, fluorortin butyl esters, fluocortolone, fluprednidene acetate (fluprednulidene), flurandrenolone, halcinodide, hydrocortisone acetate, hydrocortisone butyrate, methylprednidolone, triamcinolone acetonide, cortisone, shortdoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone, fludrocortisone, diflurosone diacetate, fluiradrenolone acetonide, medrisone, amcinafel, amcinafide, betamethasone and the balance of their esters, chloroprednisone, chlorprednisone acetate clocortelone, clescinolone, dichlorisone, diflurprednate, flucloronide, flunisolide, fluorometalone, fluperolone, fluprednisolone, valerate
of hydrocortisone, hydrocortisone cyclopentylpropionate, hydrocortamate, meprednisone, parametasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, and mixtures thereof. The preferred steroidal anti-inflammatory to be used is hydrocortisone. A second class of anti-inflammatory agents that is useful in the compositions includes non-steroidal anti-inflammatory agents. The variety of compounds encompassed by this group is well known to those skilled in the art. For a detailed description of the chemical structure, synthesis, side effects, etc. of non-steroidal anti-inflammatory agents, reference can be made to standard texts, including Anti-inflammatory and Anti-Rheumatic Druqs, K. D. Rainsford, Vols. I-III, CRC Press, Boca Raton (1985), and Anti-inflammatorv Aqents, Chemistry and Pharmacoloqy, 1, R. A. Scherrer et al, Academic Press, New York (1974), incorporated herein by reference. Specific non-steroidal anti-inflammatory agents useful in the composition of the invention include, but are not limited to: 1) oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam and CP-14,304; 2) salicylates, such as aspirin, disalcid, benorilate, trilisate, safaprin, solprin, diflunisal and fendosal; 3) acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, thiopinac,
zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac and ketorolac; 4) the fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic and tolfenamic acids; 5) propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, thioxaprofen, suprofen, alminoprofen and thiaprofenic acid; and 6) pyrazoles, such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone and trimetazone. Mixtures of these non-steroidal anti-inflammatory agents can also be used, as well as the dermatologically acceptable salts and esters of these agents. For example, etofenamate, a flufenamic acid derivative, is particularly useful for topical application. Of the non-steroidal anti-inflammatory agents, ibuprofen, naproxen, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, piroxicam and felbinac are preferred.; and ibuprofen, naproxen, etofenamate, aspirin and flufenamic acid are more preferred. Finally, so-called "natural" anti-inflammatory agents are useful in the methods of the present invention. Said agents can be suitably obtained as an extract by suitable chemical and / or physical isolation from natural sources (e.g., plants, fungi, microproduct by-products). For example, it
can candelilla wax, bisabolol alpha, Aloe vera, Manjistha (extracted from plants in the genus Rubia, particularly Rubia cordifolia), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora Mukul), kola extract, chamomile extract and algae whip shape. Other antiinflammatory agents useful herein include compounds of the Licorice family (genus / species Glycyrrhiza glabra), including glycyrrhizic acid, glycyrrhizic acid, and derivatives thereof (e.g., salts and esters). Suitable salts of the above compounds include metal and ammonium salts. Suitable esters include saturated or unsaturated C2-C24 esters of the acids, preferably C? Or-C24, more preferably C-i6-C24. Specific examples of the above include liposoluble Licorice extract, the glycyrrhizic and glycyrrhetic acids themselves, monoammonium glycyrrhizinate, monopotassium glycyrrhizinate, dipotassium glycyrrhizinate, 1-β-glycyrrheic acid, stearyl glycyrrheinate and 3-stearyloxy-glycyrrhetinic acid and 3-succinyloxy- disodium beta-glycyrrhenate. Stearyl glycyrrheate is preferred.
C. Solar filters and sunblocks Eure to ultraviolet light can result in excessive desquamation and changes in the texture of the stratum corneum. Therefore, the compositions of the present invention preferably contain a sunscreen or sunscreen. The right sunscreens or sunscreens can be organic or inorganic.
A wide variety of conventional sunscreen agents are suitable for use herein. Sagarin et al, in chapter VIII, pages 189 and consecutively from Cosmetics Science and Technology (1972), describe numerous suitable agents, and is incorporated herein by reference. Suitable specific sunscreen agents include, for example: p-aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters, p-dimethylaminobenzoic acid); anthranilates (ie, o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl and dipropylene glycol esters); cinnamic acid derivatives (menthyl and benzyl esters, a-phenyl cinnamonitrile, butyl cinnamoyl pyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylacetoumbeliferone); trihydroxycinnamic acid derivatives (esculetin, methylesculetin, daphnetin, and the glycosides esculin and daphnin); hydrocarbons (diphenylbutadiene, stilbene); dibenzalacetone and benzalacetophenone; naphtholsulfonates (sodium salts of 2-naphthol-3,6-disulfonic acid and 2-naphthol-6,8-di-sulfonyl); dihydroxynaphthoic acid and its salts; o- and p-hydroxybiphenyldisulfonates; coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl); diazoles (2-acetyl-3-bromoindazole, phenylbenzoxazole, methyl naphthoxazole, various aryl benzothiazoles); quinine salts (bisulfate, sulfate, chloride, oleate and tannate); quinoline derivatives (salts of 8-hydroxyquinoline, 2-phenylquinoline); hydroxy- or methoxy-substituted benzophenones; uric and violuric acids; tannic acid and its derivatives (for
example, hexaethyl ether); ether (butylcarbotol) (6-propyl piperonyl); hydroquinone; benzophenones (oxybenzene, sulisobenzone, dioxybenzone, benzoresorcinol, 2,2 \ 4,4'-tetrahidrox¡benzofenona, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzone; 4-isopropyldibenzoylmethane; butylmethoxydibenzoylmethane; etocrylene; octocrylene; [ 3- (4'-methylbenzylidene bornan-2-one) and 4-isopropyl-di-benzoylmethane. of these, p-methoxycinnamate, 2-ethylhexyl are preferred (commercially available as PARSOL MCX), 4,4'-t-butyl methoxydibenzoyl-methane (commercially available as PARSOL 1789), 2-hidrox¡-4-methoxybenzophenone, octyl dimethyl-p-aminobenzoic acid, digalloyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, 4- (bis (hydroxypropyl)) aminobenzoate, 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, 2-ethylhexyl salicylate, glyceryl p-aminobenzoate, 3,3,5-tri-methyl cyclohexyl-acetylate, methyl anthranilate, p-dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl p-dimethyl-aminobenzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2- (p-dimethylaminophenyl) -5-sulfonylbenzoxazoic acid, octocrylene, and mixtures of these compounds. The most preferred organic sunscreens useful in the compositions useful in the present invention are 2-ethylhexyl p-methoxycinnamate, butylmethoxydibenzoylmethane, 2-hydroxy-4-methoxybenzophenone, 2-phenylbenzimidazole-5-sulfonic acid, octyldimethyl-p-acid. aminobenzoic, octocrylene, and mixtures thereof.
Also particularly useful in the compositions are the sunscreens described in the U.S. Patent. No. 4,937,370 issued to Sabatelli on June 26, 1990, and the Patent of E.U.A. No. 4,999,186 issued to Sabatelli & Spirnak on March 12, 1991, incorporated herein by reference. The sunscreen agents described herein have, in a single molecule, two distinct chromophore portions that exhibit different absorption spectra of ultraviolet radiation. One portion of the chromophore absorbs predominantly on the UVB radiation scale, and the other absorbs strongly on the UVA radiation scale. Preferred members of this class of sunscreen agents are 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester of 2,4-dihydroxybenzophenone; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone; 4-N, N- (2-ethylhexyl) methylaminobenzoic acid ester of 4- (2-hydroxyethoxy) benzophenone; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone; and N-N-di- (2-ethylhexyl) -4-aminobenzoic acid ester of 4- (2-hydroxyethoxy) dibenzoylmethane, and mixtures thereof. Especially preferred sunscreens or sunscreens include butylmethoxydibenzoylmethane, 2-ethylhexyl p-methoxycinnamate, phenylbenzimidazole sulfonic acid, and octocrylene.
A safe and effective amount of sunscreen or sunscreen is used, typically from about 1% to about 20%, more typically from about 2% to about 10%. The exact amounts will vary, depending on the chosen sunscreen and the desired sun protection factor (SPF). An agent can also be added to any of the compositions useful in the present invention to improve the substantivity of said compositions on the skin, particularly to increase their resistance to being removed by water or being rubbed. A preferred agent that will provide this benefit is a copolymer of ethylene and acrylic acid. The compositions comprising this copolymer are described in the patent of E.U.A. 4,633,157, issued May 5, 1987, incorporated herein by reference.
D. Antioxidants / radical scavengers Preferred compositions of the present invention include an antioxidant / radical scavenger. The antioxidant / radical scavenger is especially useful to provide protection against UV radiation that can cause increased scaling or texture changes in the corneal extract, and against other environmental agents that can cause skin damage. A safe and effective amount of an antioxidant / radical scavenger may be added to the compositions of the present invention, preferably from about 0.1% to about 10%, more
preferably from about 1% to about 5%, of the composition. Antioxidants / radical scavengers may be used, such as ascorbic acid (vitamin C) and its salts, ascorbic fatty acid esters, ascorbic acid derivatives (eg, magnesium ascorbyl phosphate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other tocopherol esters, butylated hydroxybenzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox®), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its alkyl salts and esters, sorbic acid and its salts, amines (for example, N, N-diethylhydroxylamine, aminoguanidine), sulfhydryl compounds (eg, glutathione), dihydroxy-fenic acid and their salts, lichenoid pidolate, arginine pilolate, nordihydroguaracetic acid, bioflavonoids, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, extracts of peel or grape seed, melanin and rosemary extracts. Preferred antioxidants / radical scavengers are selected from tocopherol sorbate and other tocopherol esters, more preferably tocopherol sorbate. For example, the use of tocopherol sorbate in topical compositions and applicable to the present invention is described in the U.S. Pat. No. 4,847,071, issued July 11, 1989 to Donald L. Bissett, Rodney D. Bush and Ranjit Chatterjee, incorporated herein by reference.
E. Chelating agents As used herein, "chelating agent" means an active agent capable of removing a metal ion from a system through the formation of a complex, so that the metal ion can not readily participate in chemical reactions, or catalyze them. The inclusion of a chelating agent is especially useful to provide protection against UV radiation that may contribute to excessive desquamation or changes in the texture of the skin, and against other environmental agents that may cause damage to it. A safe and effective amount of a chelating agent can be added to the compositions of the present invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition. Examples of chelating agents that are useful herein are described in the U.S. Patent. No. 5,487,884, issued on 1/30/96 to Bissett et al; International Application No. 91/16035, Bush et al, published on 10/31/95; and international publication No. 91/16034, Bush et al, published on 10/31/95; all incorporated herein by reference. Preferred chelating agents useful in the compositions of the present invention are furthyloxime, and derivatives thereof.
F. Organic hydroxy acids The compositions of the present invention may comprise an organic hydroxy acid. Suitable hydroxy acids include C 1 -C 18 hydroxy acids, preferably Ca or less. The hydroxy acids can be substituted or unsubstituted, straight chain, branched chain or cyclic (preferably straight chain), and saturated or unsaturated (mono- or polyunsaturated) (preferably saturated). Non-limiting examples of suitable hydroxy acids include salicylic acid, glycolic acid, lactic acid, 5-octanoylsalicylic acid, hydroxyoctanoic acid, hydroxycaprylic acid and lanolin fatty acids. Preferred concentrations of the organic hydroxy acid vary from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2%. Salicylic acid is preferred. The organic hydroxy acids increase the appearance benefits of the skin of the present invention. Organic hydroxy acids tend to improve the texture of the skin.
G. Peeling / exfoliating agents A safe and effective amount of a desquamation agent can be added to the compositions of the present invention, more preferably from about 0.1% to about 10%, even more preferably from about 0.2% to about 5%. %, also preferably from about 0.5% to about 4%, of the
composition. Desquamation agents increase the skin appearance benefits of the present invention. For example, desquamation agents tend to improve the texture of the skin (e.g., softness). Various desquamation agents are known in the art, and are suitable for use herein including, but not limited to, the organic hydroxy agents described above. A desquamation system which is suitable for use herein comprises sulfhydryl compounds and zwitterionic surfactants, and is described in co-pending application No. 08 / 480,632, filed on June 7, 1995 in the name of Donald L. Bissett, which corresponds to the request of PCT No. US 95/08136, filed on 6/29/95, each incorporated herein by reference. Another desquamation system that is suitable for use herein includes salicylic acid and zwitterionic surfactants, and is disclosed in co-pending patent application No. 08 / 554,944, filed November 13, 1995 as a continuation of the No series. 08 / 209,401, filed on March 9, 1994 in the name of Bissett, which corresponds to PCT application No. 94/12745, filed on 4/11/94, published on 5/18/95, each incorporated in the present by reference. Zwitterionic surfactants, such as those described in these applications, are also useful as peeling agents herein, with cetylbetaine being particularly preferred.
H. Skin Lightening Agents The compositions of the present invention may comprise a skin lightening agent. When used, the compositions preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2%, of a skin lightening agent. Suitable skin lightening agents include those known in the art, including kojic acid, arbutin, ascorbic acid and derivatives thereof, for example, magnesium ascorbyl phosphate. Skin lightening agents suitable for use herein also include those described in co-pending patent application No. 08 / 479,935, filed on June 7, 1995 in the name of Hillebrand, which corresponds to the PCT application No. US 95/07432, filed on 12/12/95; and the co-pending patent application series No. 08 / 390,152, filed on February 24, 1995, to the names of Kalla L. Kvalnes, Mitchell A. DeLong, Barton J. Bradbury, Curtis B. Motley and John D. Carter, who corresponds to the PCT application No. US 95/02809, filed 3/1/95, published 9/8/95; all incorporated herein by reference.
I. Skin Conditioners Preferred compositions of the present invention comprise an optional skin conditioning component comprising one or more skin conditioning compounds. He
The skin's conditioning component is useful to lubricate it, increasing its softness and elasticity, preventing or relieving its dryness, and moisturizing and / or protecting it. The skin conditioning component enhances the skin appearance improvements of the present invention including, but not limited to, essentially immediate visual improvements in skin appearance. The skin conditioning component is preferably selected from the group consisting of emollients, humectants, moisturizers, and mixtures thereof. The skin conditioning component is preferably present at a level of at least about 0.1%, more preferably from about 1% to about 99%, even more preferably from about 1% to about 50%, even more preferably about from 2% to about 30%, and most preferably from about 5% to about 25% (eg, from about 5% to about 10% or 15%). A variety of emollients can be used. These emollients may be selected from one or more of the following classes: triglyceride esters including, but not limited to, vegetable and animal fats and oils, such as castor oil, cocoa butter, safflower oil, seed oil of cotton, corn oil, olive oil, cod liver oil, almond oil, avocado oil, palm oil, sesame oil, squalene, kikui oil and soybean oil; esters of acetoglycerides, such as acetylated monoglycerides;
ethoxylated glycerides, such as ethoxylated glyceryl monostearate; alkyl esters of fatty acids having from 10 to 20 carbon atoms and including, but not limited to, methyl, isopropyl and butyl esters of fatty acids such as hexyl laurate, isohexyl laurate, isohexyl palmitate, isopropyl palmitate methyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, isopropyl isostearate, methyl isostearate, diisopropyl adipate, diisohexyl adipate, dihexyldecyl adipate, diisopropyl sebacate, lauryl lactate, myristyl lactate and cetyl lactate; alkenyl esters of fatty acids having from 10 to 20 carbon atoms, such as oleyl myristate, oleyl stearate and oleyl oleate; fatty acids having from 10 to 20 carbon atoms, such as pelargonic, lauric, myristic, palmitic, stearic, stereostaric, hydroxystearic, oleic, linoleic, ricinoleic, arachidic, behenic and erucic acid; fatty alcohols having from 10 to 20 carbon atoms, such as lauryl, myristyl, cetyl, hexadecyl, stearyl, isostearyl, hydroxystearyl, oleyl, ricinoleyl, behenyl, erucilic and 2-octyl dodecanyl alcohol; lanolin and lanolin derivatives, such as lanolin, lanolin oil, lanolin wax, lanolin alcohols, lanolin fatty acids, isopropyl lanolate, ethoxylated cholesterol, propoxylated lanolin alcohols, acetylated lanolin alcohols, lanolin alcohol linoleate, lanolin alcohols ricinoleate, lanolin alcohol ricinoleate acetate, ethoxylated alcohol alcohols acetate, lanolin hydrogenolysis, ethoxylated hydrogenated lanolin and bases
absorption of liquid and semi-solid lanolin; polyhydric alcohol esters such as mono- and di-esters of ethylene glycol fatty acid, diethylene glycol mono- and diesters of fatty acid, mono- and di-esters of polyethylene glycol fatty acid (200-6000), mono- and di- esters of propylene glycol fatty acid, propylene glycol monooleate 2000, polypropylene glycol monostearate 2000, ethoxylated propylene glycol monostearate, glyceryl mono- and diesters of fatty acids, polyglycerol polyglyceryl esters, ethoxylated glyceryl monostearate, 1,2-butylene glycol monostearate, 1, 2-butylene glycol distearate, sorbitan fatty acid esters and sorbitan-polyoxyethylene fatty acid esters; esters of waxes such as beeswax, whale sperm, myristyl myristate, stearyl stearate; beeswax derivatives, such as sorbitol-polyoxyethylene beeswax, which are reaction products of beeswax with ethoxylated sorbitol of varying content of ethylene oxide, forming a mixture of ether esters; vegetable waxes including, but not limited to, carnauba and candelilla waxes; phospholipids such as lecithin and derivatives; sterols that include, but are not limited to, cholesterol and cholesterol fatty acid esters; and amides such as fatty acid amides, ethoxylated fatty acid amides and solid fatty acid alkanolamides. Other types of conditioning compounds are humectants of the polyhydric alcohol type. Typical polyhydric alcohols include polyalkylene glycols, and more preferably alkylene polyols and their derivatives, including propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, and
derivatives thereof, sorbitol, hydroxypropyl sorbitol, erythritol, treitol, pentaerythritol, xylitol, glucitol, mannitol, hexylene glycol, butylene glycol (for example, 1,3-butylene glycol), hexanetriol (for example, 1, 2,6-hexanetriol), glycerol, ethoxylated glycerol, propoxylated glycerol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and mixtures thereof. Also useful herein are guanidine; glycolic acid and glycolate salts (for example, ammonium and quaternary alkylammonium); lactic acid and lactate salts (for example, ammonium and quaternary alkylammonium); Aloe vera in any of its variety of forms (for example, Aloe vera gel); sugar and starch derivatives (eg, alkoxylated glucose); hyaluronic acid and derivatives thereof (e.g., salt derivatives such as sodium hyaluronate); lactate monoethanolamine; acetamide monoethanolamine; urea; panthenol; sugars; starches; silicone fluids; silicone gums; and mixtures thereof. Also useful are the propoxylated glycerols described in the U.S. Patent. No. 4,976,953, which is incorporated herein by reference. Other useful conditioning compounds include the various C 1 -C 30 monoesters and polyesters of sugars and related materials, such as those described herein in relation to the hydrophobic component. The compounds mentioned above can be incorporated individually or in combination.
Preparation of the compositions The compositions of the present invention are generally prepared by conventional methods such as those known in the art of making topical compositions. Such methods typically involve mixing the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, vacuum application, and the like.
Methods for regulating the condition of the skin The compositions of the present invention are useful for regulating the skin condition of the mammal (especially human skin, more especially human facial skin), including visible and / or tactile discontinuities in the skin, signs of aging of the skin, and visible and / or tactile discontinuities in the skin associated with skin aging (including thin lines), wrinkles, large pores, roughness of the surface and other texture discontinuities associated with aging skin). Said regulation includes the regulation that includes prophylactic and therapeutic regulation. The regulation of the condition of the skin involves the topical application to the skin of a safe and effective amount of a composition of the present invention. The amount of the composition that is applied, the frequency of application and the period of use will vary widely depending on the level of retinoid and / or other components of a given composition and the level of
desired regulation, for example, in light of the level of aging of the present skin of the subject and the speed of other aging of the skin. In a preferred embodiment, the composition is chronically applied to the skin. "Chronic topical application" refers to the continuous topical application of the composition over a long period of time during the subject's life, preferably for a period of at least about one week, more preferably for a period of at least about one month, still more preferably for at least about three months, even more preferably for at least about six months, and more preferably for at least about one year. Although the benefits are obtained after several maximum periods of use (for example, 5, 10 or 20 years), it is preferred that the chronic application continue during the life of the subject. Typically, applications will be in the order of once a day for extended periods, however, application speeds may vary from about once a week to about three times a day or more. A wide variety of amounts of the compositions of the present invention can be employed to provide benefit and appearance and / or skin feel. The amounts of the present compositions that are typically applied per application are, in mg composition / cm2 of skin, from about 0.1 mg / cm2 to about 10 mg / cm2. A particularly useful application amount is around 2 mg / cm2.
The skin regulating condition is preferably practiced by applying a composition in the form of a lotion, cream, cosmetic or the like for the skin that is intended to be left on the skin for aesthetic, prophylactic, therapeutic and other benefit benefits (ie say, an "application" composition). After applying the composition to the skin, it is preferred to apply to the skin for a period of at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, more preferably during less several hours, that is, up to about 12 hours.
EXAMPLES
The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples will be for the purpose of illustration only and are not considered as limitations of the present invention, since many variations thereof are possible without departing from the spirit and scope of the invention.
EXAMPLE 1
A stable topical composition is prepared from the following ingredients using conventional formulation techniques.
First, the ingredients of phase A were combined and sprayed using nitrogen for approximately 15 minutes. The ingredients of phase B were then dispersed in phase A until uniformed using a propellant-type mixture and the mixture was heated to about 75 ° C. In a separate vessel, the ingredients of phase C were combined and heated to about 75 ° C. The mixture of phase A and B were then covered with a slow, steady stream of nitrogen. Then, the ingredients of phase C were homogenized in the mixture of phase A and B using a rotor / stator type homogenizer for approximately
minutes. After 15 minutes, the mixture was changed to a low rpm sweep mix. Immediately afterwards, the ingredients of phase B were combined and added to the mixture of phases A, B and C. Once phase B was mixed and the charge mixture was homogeneous, the total charge mixture was cooled. When the charge was cooled to about 50 ° C, the ingredients of phase E were added and homogenized. When the load was cooled to around 40 ° C, the ingredients of phase C were added to the loading mixture. Finally, when the charge mixture was cooled to about 30 ° C, the ingredients of the G phase were combined with the charge mixture. The mixture was continued until the loading mixture was uniform. The resulting composition was useful for application to the skin to provide retinol and to treat and improve the appearance of the skin.
EXAMPLE 2
A stable topical composition was prepared from the following ingredients using conventional formulation techniques.
First, the ingredients of phase A were combined and sprayed using nitrogen for approximately 15 minutes. The ingredients of phase B were then dispersed in phase A until uniform using a propellant-type mixture and heating the mixture to about 75 ° C. In a separate container, the ingredients of phase C are
They combined and heated to around 75 ° C. The mixture of phases A and B were then covered with a slow, steady stream of nitrogen. Then, the ingredients of phase C were homogenized in the mixture of phases A and B using any type of homogenizer rotor / stator for approximately 15 minutes. After 15 minutes, the mixture was changed to a low rpm sweep mix. Once the charge mixture was homogeneous, the total charge mixture was cooled. When the load was cooled to about 50 ° C, the ingredients of phase B were added and homogenized. When the charge was cooled to about 40 ° C, the ingredients of phase E were added to the charge mixture. Finally, when the charge mixture was cooled to about 30 ° C, the ingredients of phase F were combined with the loading mixture. The mixture was continued until the loading mixture was uniform. The resulting composition was useful for application to the skin to provide the active and treat and improve the appearance of the skin.
Claims (10)
1. - A skin care composition characterized in that it comprises: a) from 0.005% to 2% of a retinoid; and b) from 0.001% to 5%, preferably from 0.05% to 0.2%, of a preservative component, comprising: i) a formaldehyde donor; ii) a halogenopropynyl compound selected from the group consisting of iodopropargyl esters, ethers, acetals, carbamates and carbonates and combinations thereof.
2. The composition according to claim 1, further characterized in that the weight ratio of the formaldehyde donor to the halogenopropynyl compound is from 2000: 1 to 1: 1.
3. The composition according to claim 1 or claim 2, further characterized in that the halogenpropynyl compound is 3-iodo-2-propynylbutylcarbamate.
4. The composition according to any of claims 1 to 3, further characterized in that the formaldehyde donor is selected from the group consisting of dimethyloldimethylstantoin, N, N "-methylenebis [N '- [hydroxymethyl] -2,5- dioxo-4-imidazolidinyl] urea]; N- (hydroxymethyl) -N- (1,3-dihydroxymethyl-2,5-dioxo-4-imidazolidinyl) -N '- (hydroxymethyl) urea; the cis isomer of 1-chloro - (3-chloroalyl) -3,5,7-triaza-1- azoniadamantane, sodium hydroxymethylglycinate, dimethyloxazoline 7-ethylbicycloxydasolidine, 2-bromo-2-nitropropan-1,3-diol, 5-bromo-5-nitro-1,3-dioxane and mixtures thereof.
5. The composition according to any of claims 1 to 4, further characterized in that the retinoid is selected from the group consisting of vitamin A alcohol, vitamin A aldehyde, retinyl acetate, retinyl palmitate and mixtures thereof.
6. The composition according to any of claims 1 to 5, further characterized in that said composition further comprises a compound selected from the group consisting of hydroxy acids, desquamating agents, sunscreens, antioxidants and combinations thereof.
7. The composition according to any of claims 1 to 6, which further comprises from 1% to 99.5% of a dermatological vehicle.
8. The composition according to any of claims 1 to 7 in the form of a lotion, a cream, gel, a bar, a sprinkler, an ointment, a paste, a mousse, or a cosmetic.
9. A method for regulating skin conditioning, which method is characterized in that it comprises the application to the skin of a mammal and a safe and effective amount of a composition according to any of claims 1 to 8.
10. - The method of regulating visible and / or tactile discontinuities in the texture of the mammalian skin whose method is further characterized by comprising the application to the skin of a mammal of a safe and effective amount of a composition according to any of the claims 1 to 8.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08862772 | 1997-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99010843A true MXPA99010843A (en) | 2000-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5968528A (en) | Skin care compositions | |
USH2043H1 (en) | Skin care compositions | |
EP0983049B2 (en) | Skin care compositions and method of improving skin appearance | |
EP0983053B1 (en) | Skin care compositions and method of improving skin appearance | |
US6001377A (en) | Skin care compositions and method of improving skin appearance | |
USH2013H1 (en) | Skin care compositions | |
US5972359A (en) | Skin care compositions and method of improving skin appearance | |
AU752126B2 (en) | Skin care compositions and method of improving skin appearance | |
MXPA99010838A (en) | Skin care compositions and method of improving skin appearance | |
WO1997039733A1 (en) | Methods of regulating skin appearance with vitamin b3 compound | |
EP0983050B1 (en) | Skin care compositions and method of improving skin appearance | |
MXPA99010843A (en) | Skin care compositions | |
MXPA99010839A (en) | Skin care compositions comprising vitamin b3 and a preservative | |
MXPA99010835A (en) | Skin care compositions and method of improving skin appearance | |
MXPA99010837A (en) | Skin care compositions and method of improving skin appearance | |
MXPA99010834A (en) | Skin care compositions and method of improving skin appearance |